<SEC-DOCUMENT>0001047469-18-006015.txt : 20180907
<SEC-HEADER>0001047469-18-006015.hdr.sgml : 20180907
<ACCEPTANCE-DATETIME>20180906214356
ACCESSION NUMBER:		0001047469-18-006015
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20180907
DATE AS OF CHANGE:		20180906

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protagonist Therapeutics, Inc
		CENTRAL INDEX KEY:			0001377121
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				980505495
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-227216
		FILM NUMBER:		181058809

	BUSINESS ADDRESS:	
		STREET 1:		7707 GATEWAY BLVD., SUITE 140
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560-1160
		BUSINESS PHONE:		(510) 474-0170

	MAIL ADDRESS:	
		STREET 1:		7707 GATEWAY BLVD., SUITE 140
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560-1160

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Protagonist Therapeutics Inc
		DATE OF NAME CHANGE:	20130605

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Protagonist Inc
		DATE OF NAME CHANGE:	20061002
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>a2236589zs-3.htm
<DESCRIPTION>S-3
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg45601_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>As filed with the Securities and Exchange Commission on September&nbsp;6, 2018  </B></FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B> Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1><B><BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1><B> <div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=1><B>Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>FORM S-3<BR>  </B></FONT><FONT SIZE=1><B>REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF&nbsp;1933  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>Protagonist Therapeutics,&nbsp;Inc.<BR>  </B></FONT><FONT SIZE=1>(Exact name of registrant as specified in its charter) </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Delaware</B></FONT><FONT SIZE=1><BR>
(State or other jurisdiction of<BR>
incorporation or organization)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B> 98-0505495</B></FONT><FONT SIZE=1><BR>
(I.R.S. Employer<BR>
Identification Number)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>7707 Gateway Boulevard, Suite&nbsp;140<BR>
Newark, California 94560-1160<BR>
(510)&nbsp;474-0170</B></FONT><FONT SIZE=1><BR>
(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Dinesh Patel<BR>
President and Chief Executive Officer<BR>
Protagonist Therapeutics,&nbsp;Inc.<BR>
7707 Gateway Boulevard, Suite&nbsp;140<BR>
Newark, California 94560-1160<BR>
(510)&nbsp;474-0170</B></FONT><FONT SIZE=1><BR>
(Name, address, including zip code, and telephone number, including area code, of agent for service) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Copies to:</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Kenneth L. Guernsey<BR>
Michael E. Tenta<BR>
Josh Seidenfeld<BR>
Cooley&nbsp;LLP<BR>
3175 Hanover Street<BR>
Palo Alto, CA 94304<BR>
(650)&nbsp;843-5000  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B> Approximate date of commencement of proposed sale to the public:<BR>
From time to time after this Registration Statement becomes effective.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following
box.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is a registration statement pursuant to General Instruction&nbsp;I.D. or a post-effective amendment thereto that shall become effective upon filing
with the Commission pursuant to Rule&nbsp;462(e) under the Securities Act, check the following box.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction&nbsp;I.D. filed to register additional securities
or additional classes of securities pursuant to Rule&nbsp;413(b) under the Securities Act, check the following box.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an
emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule&nbsp;12b-2 of the Exchange Act. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="102pt" style="font-family:times;"></TD>
<TD WIDTH="12%" style="font-family:times;"></TD>
<TD WIDTH="79pt" style="font-family:times;"></TD>
<TD WIDTH="12%" style="font-family:times;"></TD>
<TD WIDTH="96pt" style="font-family:times;"></TD>
<TD WIDTH="12%" style="font-family:times;"></TD>
<TD WIDTH="120pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Large&nbsp;accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Non-accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT><BR></FONT> <FONT SIZE=1>(Do not check if a<BR>
smaller reporting company)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;text-align:center;"><FONT SIZE=1>



<!-- COMMAND=ADD_GRID,"text-align:center;" -->


 Smaller&nbsp;reporting&nbsp;company&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></font> <p align=center style="font-family:times;margin-top:0pt;margin-left:0pt;"> <FONT SIZE=1> Emerging&nbsp;growth&nbsp;company&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>CALCULATION OF REGISTRATION FEE  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="35%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="87" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="87" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="87" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="87" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Title of Each Class of Securities<BR>
to be Registered</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Amount to be<BR>
Registered(1)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Proposed Maximum<BR>
Offering Price Per<BR>
Unit(2)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Proposed Maximum<BR>
Aggregate Offering<BR>
Price(2)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Amount of<BR>
Registration Fee(2)</B></FONT><BR></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1><B> </B></FONT><FONT SIZE=1>Common Stock, par value $0.00001 per share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>2,750,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>$9.64</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>$26,510,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>$3,301</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"> &nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 2,750,000 shares of common stock that may be issued upon the exercise of outstanding warrants. Pursuant to Rule&nbsp;416 under the Securities Act of
1933, as amended, the shares of common stock being registered hereunder include such indeterminate number of shares of common stock as may be issuable with respect to the shares of common stock being
registered hereunder as a result of stock splits, stock dividends or similar transactions.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Pursuant
to Rule&nbsp;457(c), calculated on the basis of the average of the high and low prices per share of the registrant's Common Stock reported on the Nasdaq
Global Market on September&nbsp;4, 2018, a date within five business days prior to the filing of this registration statement.  </FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=1><B>The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall
file&nbsp;a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as
amended, or until this registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may
determine.</B></FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=1>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P style="font-family:times;"><FONT SIZE=1><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=893392,FOLIO='blank',FILE='DISK104:[18ZCV1.18ZCV45601]BA45601A.;10',USER='CHE108053',CD=';6-SEP-2018;15:38' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT COLOR="#FF4040" SIZE=2><B>The information contained in this prospectus is not complete and may be changed. We may not sell these securities or accept an offer to buy these securities
until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting offers to buy these
securities in any state where such offer or sale is not permitted. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT COLOR="#FF4040" SIZE=2><B>SUBJECT TO COMPLETION, DATED SEPTEMBER&nbsp;6, 2018</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> PROSPECTUS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>2,750,000 Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>
<IMG SRC="g921274.jpg" ALT="LOGO" WIDTH="436" HEIGHT="111">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> Common Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus relates to the disposition from time to time of up to 2,750,000 shares of our common stock issuable upon the exercise of
outstanding warrants, which are held by the selling stockholders named in this prospectus. We are not selling any common stock under this prospectus and will not receive any of the proceeds from the
sale of shares by the selling stockholders. We will, however, receive the net proceeds of any warrants exercised for cash. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
selling stockholders identified in this prospectus, or their permitted transferees or other successors-in-interest that may be identified in a supplement to this prospectus or, if
required, a post-effective amendment to the registration statement of which this prospectus is a part, may offer the shares from time to time through public or private transactions at fixed prices, at
prevailing market prices, at varying prices determined at the time of sale, or at privately negotiated prices. We provide more information about how the selling stockholders may sell their shares of
common stock in the section entitled "Plan of Distribution" beginning on page&nbsp;12 of this prospectus. We have agreed to pay certain expenses incurred in connection with the registration of these
shares, however, we will not be paying any underwriting discounts or commissions in connection with any offering of common stock under this prospectus. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
common stock is listed on the NASDAQ Global Market under the symbol "PTGX." On September&nbsp;4, 2018, the last reported sale price of our common stock on the NASDAQ Global Market
was $9.51 per share. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=3><B>Investing in our common stock involves a high degree of risk. You should review carefully the risks and uncertainties incorporated by reference
herein under the heading "Risk Factors" on page&nbsp;5 of this prospectus, and under similar headings in the other documents that are filed after the date hereof and incorporated by reference into
this prospectus.</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these
securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>The
date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=988395,FOLIO='blank',FILE='DISK104:[18ZCV1.18ZCV45601]BC45601A.;20',USER='CHE108053',CD=';6-SEP-2018;15:38' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bg45601_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="BG45601A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg45601_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG45601_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#bg45601_about_this_prospectus"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>About this Prospectus</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#bg45601_about_this_prospectus"><FONT SIZE=2>i</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ca45601_prospectus_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Summary</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ca45601_prospectus_summary"><FONT SIZE=2>1</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da45601_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk Factors</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da45601_risk_factors"><FONT SIZE=2>5</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da45601_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Forward-Looking Statements</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da45601_forward-looking_statements"><FONT SIZE=2>5</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da45601_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of Proceeds</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da45601_use_of_proceeds"><FONT SIZE=2>7</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da45601_selling_stockholders"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selling Stockholders</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da45601_selling_stockholders"><FONT SIZE=2>8</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc45601_plan_of_distribution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Plan of Distribution</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc45601_plan_of_distribution"><FONT SIZE=2>12</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc45601_legal_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal Matters</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc45601_legal_matters"><FONT SIZE=2>15</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc45601_experts"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Experts</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc45601_experts"><FONT SIZE=2>15</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc45601_where_you_can_find_more_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Where You Can Find More Information</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc45601_where_you_can_find_more_information"><FONT SIZE=2>15</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc45601_incorporation_of_certain_information_by_reference"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Incorporation of Certain Information by Reference</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc45601_incorporation_of_certain_information_by_reference"><FONT SIZE=2>16</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg45601_about_this_prospectus"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT THIS PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You should carefully read this prospectus, any prospectus supplement and any related free writing prospectus, together with the additional
information described under "Where You Can Find More Information," before buying any of the securities being offered. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should rely only on the information contained in or incorporated by reference in this prospectus (as supplemented or amended). We have not authorized anyone to provide you with
different information. This prospectus may be used only in jurisdictions where offers and sales of these securities are permitted. The information contained in this prospectus, as well as the
information filed previously with the SEC, and incorporated by reference in this prospectus, is accurate only as of the date of the document containing the information, regardless of the time of
delivery of this prospectus or any applicable prospectus supplement or any sale of our common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus contains and incorporates by reference market data and industry statistics and forecasts that are based on independent industry publications and other publicly available
information. Although we believe that these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this information. Although
we are not aware of any misstatements regarding the market and industry data presented in this prospectus and the documents incorporated herein by reference, these estimates involve risks and
uncertainties and are subject to change based on various factors, including those discussed under the heading "Risk Factors" contained in the applicable prospectus supplement and any related free
writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. Accordingly, investors should not place undue reliance on this
information. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All
of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as
exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the section entitled "Where You Can Find More
Information." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise indicated herein or as the context otherwise requires, references in this prospectus to "Protagonist," "the company," "we," "us," "our" and similar references refer
to Protagonist Therapeutics,&nbsp;Inc., a corporation under the laws of the State of Delaware. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus and the information incorporated herein by reference include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and
trade
names included or incorporated by reference into this prospectus, any applicable prospectus supplement or any related free writing prospectus are the property of their respective owners. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=399337,FOLIO='i',FILE='DISK104:[18ZCV1.18ZCV45601]BG45601A.;6',USER='CHE108053',CD=';6-SEP-2018;15:38' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ca45601_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ca45601_prospectus_summary"> </A>
<A NAME="toc_ca45601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>This summary highlights selected information contained elsewhere in this prospectus or incorporated by reference herein
and does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus any applicable prospectus supplement and any
related free writing prospectus, including the risks of investing in our securities discussed under the heading "Risk Factors" contained in the applicable prospectus supplement and any related free
writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference
into this prospectus, including our financial statements and related notes, and the exhibits to the registration statement of which this prospectus is a part, before making your investment
decision.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ca45601_protagonist_therapeutics,_inc."> </A>
<A NAME="toc_ca45601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Protagonist Therapeutics,&nbsp;Inc.    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a clinical stage biopharmaceutical company with a proprietary technology platform that enables the discovery and development of novel
constrained peptide-based drug candidates that address significant unmet medical needs. Our product candidates are designed to affect critical steps in the biological pathways of particular diseases,
for example, by blocking protein-protein interactions. We believe our peptide-based approach has advantages over alternative approaches such as small molecules and antibodies. Our clinical stage
product candidates PTG-100 and PTG-200 are oral drugs that block biological pathways currently targeted by marketed injectable antibody drugs and offer targeted delivery to the gastrointestinal ("GI")
tissue compartment. We believe that, as compared to antibody drugs, these product candidates have the potential to provide improved safety due to minimal exposure in the blood, increased convenience
and compliance due to oral delivery, and the opportunity for the earlier introduction of targeted therapy. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PTG-100,
an oral, alpha-4-beta-7 ("<FONT FACE="SYMBOL">a</FONT>4<FONT FACE="SYMBOL">b</FONT>7") integrin antagonist, is being developed for potential treatment of
inflammatory bowel disease ("IBD"), a GI disease consisting primarily of&nbsp;ulcerative colitis ("UC"), and Crohn's disease ("CD"). In March 2018, we announced the discontinuation of a global
Phase&nbsp;2b clinical trial for the treatment of moderate-to-severe UC. This decision followed a planned interim analysis by an independent Data
Monitoring Committee ("DMC"). The interim data revealed an unusually high placebo rate of clinical remission that led to a futility decision and discontinuation of the trial. In August 2018, we
announced that a re-read of the endoscopies from the study by the subcontractor of the contract research organization ("CRO") and a subsequent fully blinded re-read of the endoscopies by an
independent third party confirmed that a subset of the initial endoscopy reads provided by the CRO were in error. If the re-read of endoscopy results had been utilized for the interim futility
analysis, the trial would have continued. In addition, a pre-specified blinded histopathology analysis of colon biopsies supported the observations of clinical remission and endoscopy responses for
PTG-100. Based on this entire analysis, we plan to discuss the next steps in advancing the clinical development of PTG-100 with the U.S. Food and Drug Administration ("FDA") and other global
regulatory authorities in the second half of 2018. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PTG-200
is a potential first-in-class oral, Interleukin-23 receptor ("IL-23R") antagonist for the treatment of IBD. It is currently in a Phase&nbsp;1 healthy volunteer clinical study
that was initiated in Australia in the fourth quarter of 2017. The IL-12/23 pathway blockade is an approach that has been validated through an FDA approved injectable antibody drug. We have entered
into a worldwide license and collaboration agreement with Janssen Biotech,&nbsp;Inc. ("Janssen"), a Johnson&nbsp;&amp; Johnson company, to co-develop and co-detail PTG-200 for all indications,
including IBD. See the section below entitled "Janssen License and Collaboration Agreement" for additional information. In the fourth quarter of 2018, we expect an Investigational New Drug application
("IND") in the United States by Janssen that will support the initiation of a global Phase&nbsp;2 study of PTG-200 in CD to be conducted in </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=879698,FOLIO='1',FILE='DISK104:[18ZCV1.18ZCV45601]CA45601A.;8',USER='CHE108053',CD=';6-SEP-2018;15:38' -->
<A NAME="page_ca45601_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;"><FONT SIZE=2>collaboration
with Janssen. This IND filing would trigger a milestone payment from Janssen of $25&nbsp;million under the Janssen License and Collaboration Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
novel peptides have potential applicability in a wide range of therapeutic areas in addition to GI diseases. We have applied our versatile platform outside of the GI disease areas
and are developing PTG-300, an injectable hepcidin mimetic, for the potential treatment of anemia and iron overload in certain rare blood disorders, with an initial focus on beta-thalassemia. In the
fourth quarter of 2017, we completed a successful Phase&nbsp;1 study of PTG-300 in healthy volunteers which established pharmacodynamic-based clinical proof of concept. PTG-300 received an orphan
drug designation from the FDA for the treatment of beta-thalassemia in March 2018. We completed discussions with U.S. and global regulatory agencies and filed an IND in the United States in the second
quarter of 2018. We
plan other global regulatory submissions to support the initiation of a global Phase&nbsp;2 study of PTG-300 in patients with beta-thalassemia in the fourth quarter of 2018. Treatment of patients
with myelodysplastic syndromes, hereditary hemochromatosis and polycythemia vera represent additional opportunities for future development of PTG-300. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we continue to use our peptide technology platform to discover product candidates against targets in disease areas with significant unmet medical needs. In 2018, we
anticipate initiating IND-enabling studies for a fourth product candidate, an oral peptide targeting a GI condition other than IBD. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not generated any revenue from product sales and we do not currently have any products approved for commercialization. We have never been profitable and have incurred net losses
in each year since inception and we do not anticipate that we will achieve sustained profitability in the near term. Our net losses were $8.7&nbsp;million and $16.3&nbsp;million for the three and
six months ended June&nbsp;30, 2018, respectively, and $15.0&nbsp;million and $29.1&nbsp;million for the three and six months ended June&nbsp;30, 2017, respectively. As of June&nbsp;30,
2018, we had an accumulated deficit of $117.9&nbsp;million. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from
general and administrative costs associated with our operations. We expect to continue to incur significant research, development and other expenses related to our ongoing operations and product
development, including clinical development activities under the Janssen License and Collaboration Agreement, and as a result, we expect to continue to incur losses in the future as we continue our
development of, and seek regulatory approval for, our product candidates. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Janssen License and Collaboration Agreement  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On May&nbsp;26, 2017, we and Janssen, one of the Janssen Pharmaceutical Companies of Johnson&nbsp;&amp; Johnson, entered into an exclusive
license and collaboration agreement (the "Janssen License and Collaboration Agreement") for the clinical development, manufacture and potential commercialization of PTG-200 worldwide for the treatment
of CD and UC. Janssen is a related party to us as Johnson&nbsp;&amp; Johnson Innovation&#151;JJDC,&nbsp;Inc., a significant stockholder of ours, and Janssen are both subsidiaries of
Johnson&nbsp;&amp; Johnson. During the third quarter of 2017, we received a non-refundable, upfront cash payment of $50.0&nbsp;million from Janssen. We can also receive up to an additional
$940.0&nbsp;million in payments, including potential license option payments of $125.0&nbsp;million at the Phase&nbsp;2 interim analysis and $200.0&nbsp;million at Phase&nbsp;2 completion,
and $615.0&nbsp;million in other potential clinical development, regulatory approval and sales milestones. We and Janssen will co-develop and co-fund PTG-200 through Phase&nbsp;2 clinical
development. Janssen will be responsible for funding Phase&nbsp;3 studies in CD and UC. We will receive double-digit tiered royalties on future net sales and retain the option to co-detail PTG-200
in the United States. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=5,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=596108,FOLIO='2',FILE='DISK104:[18ZCV1.18ZCV45601]CA45601A.;8',USER='CHE108053',CD=';6-SEP-2018;15:38' -->
<A NAME="page_ca45601_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Company Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protagonist Pty Limited (Protagonist Australia) was incorporated in Australia in September 2001. We were incorporated under the laws of the
State of Delaware in 2006, under the name Protagonist Therapeutics,&nbsp;Inc., and became the parent of Protagonist Australia pursuant to a transaction in which all of the issued and outstanding
capital stock of Protagonist Australia was exchanged for shares of our common stock and Series&nbsp;A preferred stock. Our principal executive offices are located at 7707&nbsp;Gateway Boulevard,
Suite&nbsp;140, Newark, California 94560. Our telephone number is (510)&nbsp;474-0170. Our website address is www.protagonist-inc.com. The information contained in, or accessible through, our
website does not constitute part of this prospectus, should not be relied on in determining whether to make an investment decision, and the inclusion of our website address in this prospectus is an
inactive textual reference only. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Protagonist logo and other trademarks or service marks of Protagonist Therapeutics,&nbsp;Inc. appearing in this prospectus are the property of Protagonist Therapeutics,&nbsp;Inc.
Other trademarks, service marks or trade names appearing in this prospectus are the property of their respective owners. We do not intend our use or display of other companies' trade names, trademarks
or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Private Placement  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On August&nbsp;6, 2018, we entered into a securities purchase agreement, pursuant to which we agreed to sell and issue to the selling
stockholders warrants to purchase an aggregate of 2,750,000 shares of Common Stock (each, a "Warrant," and collectively, the "Warrants"). Each Warrant is exercisable from August&nbsp;8, 2018 until
August&nbsp;8, 2023. Warrants to purchase 1,375,000 shares of Common Stock have an exercise price of $10.00 per share (the "Class&nbsp;A Warrants") and Warrants to
purchase 1,375,000 shares of Common Stock have an exercise price of $15.00 per share (the "Class&nbsp;B Warrants"). The exercise price and number of shares of Common Stock issuable upon the exercise
of the Warrants (the "Warrant Shares") is subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as
described in the Warrants. Under certain circumstances, the Warrants will be exercisable on a "cashless" basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the issuance and sale of the Warrants, we granted certain registration rights with respect to the Warrants and the Warrant Shares, pursuant to a Registration Rights
Agreement by and among us and the selling stockholders (the "Rights Agreement"). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
required by the Rights Agreement, we agreed to, among other things, (i)&nbsp;file&nbsp;a registration statement with the SEC to cover the resale of the Warrant Shares by the
selling stockholders, (ii)&nbsp;use commercially reasonable efforts to cause such registration statement to become effective following the filing thereof and (iii)&nbsp;take all other actions as
may be necessary to keep such registration statement continuously effective during the timeframes set forth in the Rights Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registration statement of which this prospectus is a part relates to the resale of the Warrant Shares that may be issued to the selling stockholders in connection with the exercise
of the Warrants issued in the foregoing private placement. Shares of common stock that may be offered under this prospectus will be fully paid and non-assessable. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=6,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=830142,FOLIO='3',FILE='DISK104:[18ZCV1.18ZCV45601]CA45601A.;8',USER='CHE108053',CD=';6-SEP-2018;15:38' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_cc45601_1_4"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cc45601_the_offering"> </A>
<A NAME="toc_cc45601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  The Offering    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock offered by selling stockholders</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>2,750,000 shares</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Term of offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Each selling stockholder will determine when and how it will sell the common stock offered in this prospectus, as described
in "Plan of Distribution."</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of proceeds</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We will not receive any proceeds from the sale of shares of our common stock by the selling stockholders.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk factors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>See the section below entitled "Risk Factors" for a discussion of factors you should carefully consider before deciding to
invest in our common stock.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nasdaq Global Market Symbol</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PTGX</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
selling stockholders named in this prospectus may offer and sell up to 2,750,000 shares of our common stock. Our common stock is currently listed on The Nasdaq Global Market under
the symbol "PTGX." Shares of common stock that may be offered under this prospectus will be fully paid and non-assessable. We will not receive any of the proceeds of sales by the selling stockholders
of any of the common stock covered by this prospectus. Throughout this prospectus, when we refer to the shares of our common stock being registered on behalf of the selling stockholders for offer and
resale, we are referring to the shares of common stock issued to the selling stockholders in connection with the exercise of Warrants issued in our private placement as described above. When we refer
to the selling stockholders in this prospectus, we are referring to the selling stockholders identified in this prospectus and, as applicable, their permitted transferees or other
successors-in-interest that may be identified in a supplement to this prospectus or, if required, a post-effective amendment to the registration statement of which this prospectus is a part. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=7,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=444196,FOLIO='4',FILE='DISK104:[18ZCV1.18ZCV45601]CC45601A.;7',USER='CHE108053',CD=';6-SEP-2018;15:38' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_da45601_1_5"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da45601_risk_factors"> </A>
<A NAME="toc_da45601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investing in our common stock involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully
the risks and uncertainties described under the heading "Risk Factors" contained in our most recent Annual Report on Form&nbsp;10-K and in our most recent Quarterly Report on Form&nbsp;10-Q, as
well as any amendments thereto reflected in subsequent filings with the SEC, which are incorporated by reference into this prospectus in their entirety, together with other information in this
prospectus, the documents incorporated by reference and any free writing prospectus that we may authorize for use in connection with this offering. The risks described in these documents are not the
only ones we face, but those that we consider to be material. There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors that could have material adverse
effects on our future results. Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future
periods. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be seriously harmed. This could cause the trading price of our common stock
to decline, resulting in a loss of all or part of your investment. Please also read carefully the section below entitled "Forward-Looking Statements." </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da45601_forward-looking_statements"> </A>
<A NAME="toc_da45601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus, the documents incorporated by reference any applicable prospectus supplement and any free writing prospectus that we have
authorized for use in connection with this offering contain forward-looking statements, including statements regarding our future financial condition, business strategy and plans and objectives of
management for future operations. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as
"believe," "will," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "might," "approximately," "expect," "predict," "could," "potentially" or the negative of these terms or
other similar expressions. Forward-looking statements appear in a number of places throughout this prospectus, the documents incorporated by reference and any free writing prospectus that we have
authorized for use in connection with this offering and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the
potential for our programs, the timing of our clinical trials, the potential for eventual regulatory approval and commercialization of our product candidates and our potential receipt of milestone
payments and royalties under our collaboration agreement with Janssen, the potential outcome of any litigation or proceeding, future operating results or the ability to generate sales, income or cash
flow are forward-looking statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Discussions
containing these forward-looking statements may be found, among other places, in the sections entitled "Risk Factors," "Business" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" incorporated by reference from our most recent Annual Report on Form&nbsp;10-K and our Quarterly Reports on Form&nbsp;10-Q, as well as any amendments
thereto, filed with SEC. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that could cause our actual
results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. These statements reflect our current views with
respect to future events and are based on assumptions and subject to risks and uncertainties. Given these risks and uncertainties, you should not place undue reliance on these forward-looking
statements. We discuss in greater detail many of these risks under the heading "Risk Factors" in the documents incorporated by reference herein, and elsewhere in this prospectus. Also, these
forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement and, except as required by law, we undertake no obligation to
update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=8,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=275757,FOLIO='5',FILE='DISK104:[18ZCV1.18ZCV45601]DA45601A.;20',USER='CHE109873',CD=';6-SEP-2018;18:04' -->
<A NAME="page_da45601_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as
of the date of this
prospectus, and while we believe such information forms&nbsp;a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate
that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly
rely upon these statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=9,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=950189,FOLIO='6',FILE='DISK104:[18ZCV1.18ZCV45601]DA45601A.;20',USER='CHE109873',CD=';6-SEP-2018;18:04' -->
<A NAME="page_da45601_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da45601_use_of_proceeds"> </A>
<A NAME="toc_da45601_3"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The selling stockholders will receive all of the net proceeds from sales of the common stock sold pursuant to this prospectus. However, upon any
exercise of Warrants for cash, the selling stockholders would pay us an exercise price of $10.00 per share of common stock in the case of Class&nbsp;A Warrants, and $15.00 per share of common stock
in the case of Class&nbsp;B Warrants, subject to any adjustment pursuant to the terms of the Warrants. We expect to use any such Warrant exercise proceeds primarily for working capital and general
corporate purposes. Under certain circumstances, the Warrants are exercisable on a cashless basis by net exercise. If any of the Warrants are exercised on a cashless basis, we would not receive any
cash payment from the applicable selling stockholder upon any such cashless exercise of a Warrant. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=10,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=1032341,FOLIO='7',FILE='DISK104:[18ZCV1.18ZCV45601]DA45601A.;20',USER='CHE109873',CD=';6-SEP-2018;18:04' -->
<A NAME="page_da45601_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da45601_selling_stockholders"> </A>
<A NAME="toc_da45601_4"> </A>
<BR></FONT><FONT SIZE=2><B>  SELLING STOCKHOLDERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are registering the resale of 2,750,000 shares of common stock which are issuable upon the exercise of Warrants held by the selling
stockholders identified below to permit each of them, or their permitted transferees or other successors-in-interest that may be identified in a supplement to this prospectus or, if required, a
post-effective amendment to the registration statement
of which this prospectus is a part, to resell or otherwise dispose of these shares in the manner contemplated under the section entitled "Plan of Distribution" in this prospectus (as may be
supplemented and amended). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
selling stockholders may sell some, all or none of their shares. We do not know how long the selling stockholders will hold the shares before selling them, and we currently have no
agreements, arrangements or understandings with the selling stockholders regarding the sale or other disposition of any of the shares. The shares covered hereby may be offered from time to time by the
selling stockholders. As a result, we cannot estimate the number of shares of common stock each of the selling stockholders will beneficially own after termination of sales under this prospectus. In
addition, each of the selling stockholders may have sold, transferred or otherwise disposed of all or a portion of its shares of common stock since the date on which it provided information for this
table. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to our common stock. Generally, a person "beneficially
owns" shares of our common stock if the person has or shares with others the right to vote those shares or to dispose of them, or if the person has the right to acquire voting or disposition rights
within 60&nbsp;days. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
information in the table below and the footnotes thereto regarding shares of common stock to be beneficially owned after the offering assumes the sale of all shares being offered by
the selling stockholders under this prospectus. The percentage of shares owned prior to and after the offering is based on 24,085,588 shares of common stock outstanding as of August&nbsp;15, 2018.
This information has </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=11,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=266888,FOLIO='8',FILE='DISK104:[18ZCV1.18ZCV45601]DA45601A.;20',USER='CHE109873',CD=';6-SEP-2018;18:04' -->
<A NAME="page_da45601_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>been
obtained from the selling stockholders or in Schedules&nbsp;13G or 13D and other public documents filed with the SEC. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Prior to Offering </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>After Offering(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Address

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Beneficially<BR>
Owned(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage of<BR>
Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Offered(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage of<BR>
Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>BVF Partners&nbsp;L.P.</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,867,967</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,250,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,617,967</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 44 Montgomery Street, 40th&nbsp;Floor</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 San Francisco, CA 94104</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Farallon Capital Offshore Investors II,&nbsp;LP</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,829,684</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>746,200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,083,484</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>c/o Farallon Capital Management, L.L.C.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>One Maritime Plaza, #2100</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>San Francisco, CA 94111</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>Farallon Capital Institutional Partners,&nbsp;LP</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>764,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>292,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>472,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 c/o Farallon Capital Management, L.L.C.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 One Maritime Plaza, #2100</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 San Francisco, CA 94111</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Farallon Capital Partners,&nbsp;LP</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>723,300</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>277,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>445,800</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>c/o Farallon Capital Management, L.L.C.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>One Maritime Plaza, #2100</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>San Francisco, CA 94111</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>Farallon Capital Institutional Partners II,&nbsp;LP</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>132,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(8)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>52,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>79,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 c/o Farallon Capital Management, L.L.C.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 One Maritime Plaza, #2100</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 San Francisco, CA 94111</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Four Crossings Institutional Partners V,&nbsp;L.P.</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>113,100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(9)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>45,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>68,100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>c/o Farallon Capital Management, L.L.C.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>One Maritime Plaza, #2100</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>San Francisco, CA 94111</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>Farallon Capital F5 Master I,&nbsp;L.P.</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>92,600</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(10)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>37,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>55,100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 c/o Farallon Capital Management, L.L.C.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 One Maritime Plaza, #2100</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 San Francisco, CA 94111</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Farallon Capital Institutional Partners III,&nbsp;LP</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>90,400</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(11)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>33,800</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>56,600</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>c/o Farallon Capital Management, L.L.C.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>One Maritime Plaza, #2100</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>San Francisco, CA 94111</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>Farallon Capital (AM) Investors,&nbsp;LP</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>44,300</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(12)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>29,300</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 c/o Farallon Capital Management, L.L.C.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 One Maritime Plaza, #2100</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 San Francisco, CA 94111</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Less
than 1%
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Under
the terms of the Warrants, the number of shares of our common stock that may be acquired by a selling stockholder upon any exercise of a Warrant is generally
limited to the extent necessary to ensure that, following such exercise, such selling stockholder would not, together with its affiliates and any other persons or entities whose beneficial ownership
of our common stock would be aggregated with such selling stockholder for purposes of Section&nbsp;13(d) of the Exchange Act, beneficially own in excess of 9.99% of the total number of shares of our
common stock then issued and outstanding and/or the then combined voting power of all of our voting securities (the </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=12,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=110786,FOLIO='9',FILE='DISK104:[18ZCV1.18ZCV45601]DA45601A.;20',USER='CHE109873',CD=';6-SEP-2018;18:04' -->
<A NAME="page_da45601_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
<UL>

<P style="font-family:times;"><FONT SIZE=2>"Blockers");
provided, that such Blocker is waivable by the selling stockholder upon notice to us up to a 19.99% maximum. As noted in footnote (2), the number of shares shown under the column titled
"Number of Shares Offered" is shown without regard to the foregoing limitations on exercise.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
number of shares offered hereby, for each selling stockholder, consists solely of the shares issuable upon exercise of the Class&nbsp;A Warrants and
Class&nbsp;B Warrants issued to such selling stockholder. The shares issuable upon exercise of the warrants will become eligible for sale by the selling stockholders under this prospectus only as
the warrants are exercised. In addition, the number of shares offered hereby shown under the column titled "Number of Shares Offered" includes the maximum number of shares issuable upon the exercise
of the Warrants without regard to the limitations on exercise described in footnote (1)&nbsp;above.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Assumes
sale of all shares available for sale under this prospectus and no further acquisitions of shares by the selling stockholders.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of (i)&nbsp;1,209,268 outstanding shares of common stock owned by Biotechnology Value Fund,&nbsp;L.P. ("BVF") and 577,541 shares of common stock
issuable upon the exercise of warrants held by BVF, (ii)&nbsp;951,770 outstanding shares of common stock owned by Biotechnology Value Fund&nbsp;II,&nbsp;L.P. ("BVF2") and 454,455 shares of
common stock issuable upon the exercise of warrants held by BVF2, (iii)&nbsp;199,196 outstanding shares of common stock owned by Biotechnology Value Trading Fund OS,&nbsp;L.P. ("Trading Fund OS")
and 88,264 shares of common stock issuable upon the exercise of warrants held by Trading Fund OS, (iv)&nbsp;98,347 outstanding shares of common stock owned by Investment 10, LLC ("INV10") and 44,748
shares of common stock issuable upon the exercise of warrants held by ("INV10") and (v)&nbsp;159,386 outstanding shares of common stock owned by MSI BVF SPV, L.L.C. ("MSI" and together with BVF,
BVF2, Trading Fund OS and INV10, the "BVF Investment Entities") and 84,992 shares of common stock issuable upon the exercise of warrants held by MSI. BVF Partners L.P. ("BVF Partners") is the general
partner of BVF and BVF2, and the investment manager of each of Trading Fund OS, INV10 and MSI, and may be deemed to beneficially own the shares held by the BVF Investment Entities. BVF, Inc., as the
general partner of BVF Partners, may be deemed to beneficially own the shares beneficially owned by BVF Partners. Mark Lampert, as a director and officer of BVF, Inc., may be deemed to beneficially
own the shares beneficially owned by BVF, Inc.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of (i)&nbsp;1,083,484 outstanding shares of common stock owned by Farallon Capital Offshore Investors II,&nbsp;LP ("FCOI II") and (ii)&nbsp;746,200
shares of common stock issuable upon the exercise of warrants held by FCOI II. Each of Philip D. Dreyfuss, Michael B. Fisch, Richard B. Fried, David T. Kim, Monica R. Landry, Michael G. Linn, Rajiv A.
Patel, Thomas G. Roberts, Jr., William Seybold, Andrew J.M. Spokes, John R. Warren and Mark C. Wehrly (collectively, the "Managing Members"), as a managing member or senior managing member of the
general partner, share voting and dispositive power with respect to the shares held by FCOI II. Each of the Managing Members disclaims beneficial ownership of such shares except to the extent of his
or her pecuniary interest therein.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of (i)&nbsp;472,000 outstanding shares of common stock owned by Farallon Capital Institutional Partners,&nbsp;LP ("FCIP") and (ii)&nbsp;292,500 shares
of common stock issuable upon the exercise of warrants held by FCIP. Each of the Managing Members, as a managing member or senior managing member of the general partner, share voting and dispositive
power with respect to the shares held by FCIP. Each of the Managing Members disclaims beneficial ownership of such shares except to the extent of his or her pecuniary interest therein.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of (i)&nbsp;445,800 outstanding shares of common stock owned by Farallon Capital Partners,&nbsp;LP ("FCP") and (ii)&nbsp;277,500 shares of common
stock issuable upon the exercise of warrants held by FCP. Each of the Managing Members, as a managing member or senior managing member of the general partner, share voting and dispositive power with
respect to the shares held by FCP. Each of </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=13,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=1036200,FOLIO='10',FILE='DISK104:[18ZCV1.18ZCV45601]DA45601A.;20',USER='CHE109873',CD=';6-SEP-2018;18:04' -->
<A NAME="page_da45601_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=2>the
Managing Members disclaims beneficial ownership of such shares except to the extent of his or her pecuniary interest therein.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of (i)&nbsp;79,500 outstanding shares of common stock owned by Farallon Capital Institutional Partners II,&nbsp;LP ("FCIP II") and (ii)&nbsp;52,500
shares of common stock issuable upon the exercise of warrants held by FCIP II. Each of the Managing Members, as a managing member or senior managing member of the general partner, share voting and
dispositive power with respect to the shares held by FCIP II. Each of the Managing Members disclaims beneficial ownership of such shares except to the extent of his or her pecuniary interest therein.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of (i)&nbsp;68,100 outstanding shares of common stock owned by Four Crossings Institutional Partners V,&nbsp;L.P. ("Four CIP V") and (ii)&nbsp;45,000
shares of common stock issuable upon the exercise of warrants held by Four CIP V. Each of the Managing Members, as a manager or senior manager of the general partner, share voting and dispositive
power with respect to the shares held by Four CIP V. Each of the Managing Members disclaims beneficial ownership of such shares except to the extent of his or her pecuniary interest therein.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of (i)&nbsp;55,100 outstanding shares of common stock owned by Farallon Capital F5 Master&nbsp;I,&nbsp;L.P. ("FCF5M") and (ii)&nbsp;37,500 shares
of common stock issuable upon the exercise of warrants held by FCF5M. Each of the Managing Members, as a manager or senior manager of the general partner, share voting and dispositive power with
respect to the shares held by FCF5M. Each of the Managing Members disclaims beneficial ownership of such shares except to the extent of his or her pecuniary interest therein.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of (i)&nbsp;56,600 outstanding shares of common stock owned by Farallon Capital Institutional Partners III,&nbsp;LP ("FCIPIII") and (ii)&nbsp;33,800
shares of common stock issuable upon the exercise of warrants held by FCIPIII. Each of the Managing Members, as a managing member or senior managing member of the general partner, share voting and
dispositive power with respect to the shares held by FCIPIII. Each of the Managing Members disclaims beneficial ownership of such shares except to the extent of his or her pecuniary interest therein.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(12)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of (i)&nbsp;29,300 outstanding shares of common stock owned by Farallon Capital (AM) Investors,&nbsp;LP ("FCAMI") and (ii)&nbsp;15,000 shares of
common stock issuable upon the exercise of warrants held by FCAMI. Each of the Managing Members, as a managing member or senior managing member of the general partner, share voting and dispositive
power with respect to the shares held by FCAMI. Each of the Managing Members disclaims beneficial ownership of such shares except to the extent of his or her pecuniary interest therein. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=14,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=335265,FOLIO='11',FILE='DISK104:[18ZCV1.18ZCV45601]DA45601A.;20',USER='CHE109873',CD=';6-SEP-2018;18:04' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc45601_1_12"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc45601_plan_of_distribution"> </A>
<A NAME="toc_dc45601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PLAN OF DISTRIBUTION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are registering the shares of common stock issuable to the selling stockholders upon the exercise of the selling stockholders' Warrants to
permit the resale of such shares of common stock by such holders from time to time after the date of this prospectus. We will not receive any of the proceeds from the sale by the selling stockholders
of the shares of common stock. We will bear all fees and expenses incident to our obligation to register such shares of common stock. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
selling stockholder, which may include donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests in shares of common stock received
after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of
its shares of common stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be
at fixed prices, at
prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at privately negotiated prices. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
selling stockholder may use any one or more of the following methods when disposing of shares or interests therein:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as
principal to facilitate the transaction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> purchases by a broker-dealer as principal and resale by the broker-dealer for its own account; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an exchange distribution in accordance with the rules of the applicable exchange; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> privately negotiated transactions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to the extent permitted by law, short sales effected after the date the registration statement of which this prospectus is a part is declared
effective by the SEC; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> through agreements between broker-dealers and the selling stockholders to sell a specified number of such shares at a stipulated price per
share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a combination of any such methods of sale; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any other method permitted by applicable law. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
selling stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of
their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under
Rule&nbsp;424(b) or other applicable provision of the Securities Act amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling
stockholders under this prospectus. The selling stockholders also may transfer the shares of common stock in other circumstances, in which case the pledgees, transferees or other successors in
interest will be the selling beneficial owners for purposes of this prospectus. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the sale of our common stock or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions,
which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of our common stock short and deliver
these securities to close </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=15,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=742216,FOLIO='12',FILE='DISK104:[18ZCV1.18ZCV45601]DC45601A.;6',USER='CHE108053',CD=';6-SEP-2018;15:38' -->
<A NAME="page_dc45601_1_13"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>out
their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into options or other transactions with
broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to each such broker-dealer or other financial institution of shares
offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions, if any.
Each of the selling stockholders reserves the right to accept and, together with its agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly
or through agents. We will not receive any of the proceeds from this offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
selling stockholders also may resell all or a portion of the shares in open market transactions, rather than under this prospectus, in reliance upon Rule&nbsp;144 under the
Securities Act, provided that they meet the criteria and conform to the requirements of that rule. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
selling stockholders and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be "underwriters" within the meaning of
Section&nbsp;2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities
Act. Selling stockholders who are "underwriters" within the meaning of Section&nbsp;2(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent required, the shares of our common stock to be sold, the names of the selling stockholders, the respective purchase prices and public offering prices, the names of any
agents, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a
post-effective amendment to the registration statement that includes this prospectus. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
underwriters are used in the sale, the shares of common stock will be acquired by the underwriters for their own account and may be resold from time to time in one or more
transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. In connection with any such underwritten sale of shares of common
stock, underwriters may receive compensation from the selling stockholders, for whom they may act as agents, in the form of discounts, concessions or commissions. If the selling stockholders use an
underwriter or underwriters to effectuate the sale of shares of common stock, we and/or they will execute an underwriting agreement with those underwriters at the time of sale of those shares of
common stock. To the extent required by law, the names of the underwriters will be set forth in a prospectus supplement or, if appropriate, a post-effective amendment to the registration statement
that includes the prospectus supplement and the accompanying prospectus used by the underwriters to sell those securities. The obligations of the underwriters to purchase those shares of common stock
will be subject to certain conditions precedent, and unless otherwise specified in a prospectus supplement, the underwriters will be obligated to purchase all the shares of common stock offered by
such prospectus supplement if any of such shares of common stock are purchased. Any public offering price and any discounts or concessions allowed or re-allowed or paid to dealers may be changed from
time to time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have advised the selling stockholders that the anti-manipulation rules of Regulation&nbsp;M under the Exchange Act may apply to sales of shares in the market and to the activities
of the selling stockholders and their affiliates. The selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain
liabilities, including liabilities arising under the Securities Act. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=16,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=136637,FOLIO='13',FILE='DISK104:[18ZCV1.18ZCV45601]DC45601A.;6',USER='CHE108053',CD=';6-SEP-2018;15:38' -->
<A NAME="page_dc45601_1_14"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are required to pay certain fees and expenses incurred by us incident to the registration of the shares of common stock of the selling stockholders. We have agreed to indemnify the
selling stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act, and the selling stockholders may be entitled to contribution. We may be
indemnified by the selling stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act that may arise from any written information furnished to
us by the selling stockholders specifically for use in this prospectus, or we may be entitled to contribution. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have agreed with the selling stockholders to keep the registration statement of which this prospectus constitutes a part effective until the earlier of (1)&nbsp;such time as all of
the shares covered by this prospectus have been disposed of pursuant to and in accordance with the registration statement or pursuant to Rule&nbsp;144 of the Securities Act or
(2)&nbsp;August&nbsp;8, 2020. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=17,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=518142,FOLIO='14',FILE='DISK104:[18ZCV1.18ZCV45601]DC45601A.;6',USER='CHE108053',CD=';6-SEP-2018;15:38' -->
<A NAME="page_dc45601_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc45601_legal_matters"> </A>
<A NAME="toc_dc45601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cooley&nbsp;LLP will pass upon the validity of the securities offered pursuant to this registration statement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc45601_experts"> </A>
<A NAME="toc_dc45601_3"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The financial statements incorporated in this registration statement by reference to the Annual Report on Form&nbsp;10-K for the year ended
December&nbsp;31, 2017 have been so incorporated in reliance on the report of PricewaterhouseCoopers&nbsp;LLP, an independent registered public accounting firm, given on the authority of said firm
as experts in auditing and accounting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc45601_where_you_can_find_more_information"> </A>
<A NAME="toc_dc45601_4"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND MORE INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in
the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the
registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with
different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any
date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy any document we file with the SEC at the SEC's public reference
room at 100&nbsp;F Street, N.E., Washington, D.C., 20549. Please call the SEC at 1.800.SEC.0330 for further information on the operation of the public reference room. Our SEC filings are also
available to the public at the SEC's website at http://www.sec.gov. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=18,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=958938,FOLIO='15',FILE='DISK104:[18ZCV1.18ZCV45601]DC45601A.;6',USER='CHE108053',CD=';6-SEP-2018;15:38' -->
<A NAME="page_dc45601_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc45601_incorporation_of_certain_information_by_reference"> </A>
<A NAME="toc_dc45601_5"> </A>
<BR></FONT><FONT SIZE=2><B>  INCORPORATION OF CERTAIN INFORMATION BY REFERENCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC allows us to "incorporate by reference" the information we file with it, which means that we can disclose important information to you
by referring you to those documents instead of having to repeat the information in this prospectus. The information incorporated by reference is considered to be part of this prospectus, and later
information that we file with the SEC will automatically update and supersede this information. We incorporate by reference the documents listed below and any future filings (including those made
after the date of the initial filing of the registration statement of which this prospectus is a part and prior to the effectiveness of such registration statement) we will make with the SEC under
Sections&nbsp;13(a), 13(c), 14, or 15(d) of the Exchange Act until the termination of the offering of the shares covered by this prospectus (other than information furnished under Item&nbsp;2.02
or Item&nbsp;7.01 of Form&nbsp;8-K):</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our annual report on Form&nbsp;10-K for the year ended December&nbsp;31, 2017, filed with the SEC on March&nbsp;7, 2018, including the
information specifically incorporated by reference therein from our definitive proxy statement on Schedule&nbsp;14A, filed on April&nbsp;18, 2018; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our Quarterly Report on Form&nbsp;10-Q for the quarter ended March&nbsp;31, 2018, filed with the SEC on May&nbsp;9, 2018; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2018, filed with the SEC on August&nbsp;7, 2018; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our current reports on Form&nbsp;8-K, filed with the SEC on February&nbsp;27, 2018, March&nbsp;26, 2018, May&nbsp;16, 2018,
May&nbsp;31, 2018 and August&nbsp;7, 2018; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the description of our common stock set forth in our registration statement on Form&nbsp;8-A, filed with the SEC on August&nbsp;9, 2016,
including any amendments thereto or reports filed for the purposes of updating this description. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
can request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Protagonist
Therapeutics,&nbsp;Inc.<BR>
7707 Gateway Boulevard, Suite&nbsp;140<BR>
Newark, California 94560<BR>
(510)&nbsp;474-0170<BR>
Attn: Chief Financial Officer </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus is part of a registration statement we filed with the SEC. That registration statement and the exhibits filed along with the registration statement contain more
information about us and the shares in this offering. Because information about documents referred to in this prospectus is not always complete, you should read the full documents which are filed as
exhibits to the registration statement. You may read and copy the full registration statement and its exhibits at the SEC's public reference rooms or its website. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=19,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=338893,FOLIO='16',FILE='DISK104:[18ZCV1.18ZCV45601]DC45601A.;6',USER='CHE108053',CD=';6-SEP-2018;15:38' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ja45601_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ja45601_part_ii_information_not_required_in_the_prospectus"> </A>
<A NAME="toc_ja45601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PART II<BR>  INFORMATION NOT REQUIRED IN THE PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja45601_item_14._other_expense__ja401990"> </A>
<A NAME="toc_ja45601_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;Other Expenses of Issuance and Distribution.    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following sets forth the estimated costs and expenses, all of which shall be borne by the Registrant, in connection with the offering of the
securities pursuant to this Registration Statement: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SEC Registration Fee</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,301</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal Fees and Expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>125,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounting Fees</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Printing and Miscellaneous Fees</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>30,699 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>169,000 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><A
NAME="ja45601_item_15._indemnification_of_directors_and_officers."> </A>
<A NAME="toc_ja45601_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers.    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;145 of the Delaware General Corporation Law authorizes a court to award, or a corporation's board of directors to grant,
indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under
the Securities Act. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
certificate of incorporation provides for indemnification of our directors, officers, employees and other agents to the maximum extent permitted by the Delaware General Corporation
Law, and our bylaws provide for indemnification of our directors, officers, employees and other agents to the maximum extent permitted by the Delaware General Corporation Law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have entered into indemnification agreements with our directors and officers whereby we have agreed to indemnify our directors and officers to the fullest extent permitted by law,
including indemnification against expenses and liabilities incurred in legal proceedings to which the director or officer was, or is threatened to be made, a party by reason of the fact that such
director or officer is or was a director, officer, employee or agent of Protagonist, provided that such director or officer acted in good faith and in a manner that the director or officer reasonably
believed to be in, or not opposed to, the best interest of Protagonist. At present, there is no pending litigation or proceeding involving a director or officer of Protagonist regarding which
indemnification is sought, nor is the registrant aware of any threatened litigation that may result in claims for indemnification. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
maintain insurance policies that indemnify our directors and officers against various liabilities arising under the Securities Act and the Exchange Act of 1934, as amended, that might
be incurred by any director or officer in his capacity as such. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriting agreement(s) that the Registrant may enter into may provide for indemnification by any underwriters of the Registrant, its directors, its officers who sign the
registration statement and the Registrant's controlling persons for some liabilities, including liabilities arising under the Securities Act. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=20,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=890308,FOLIO='II-1',FILE='DISK104:[18ZCV1.18ZCV45601]JA45601A.;9',USER='CHE108053',CD=';6-SEP-2018;15:38' -->
<A NAME="page_ja45601_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja45601_item_16._exhibits_and_financial_statement_schedules"> </A>
<A NAME="toc_ja45601_4"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;16.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits and Financial Statement Schedules    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="15pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1377121/000119312516683189/d237730dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant, as amended.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>3.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>(2)</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1377121/000119312516665762/d144462dex32b.htm">Amended and Restated Bylaws of the Registrant.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>(2)</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1377121/000119312516665762/d144462dex41.htm">Specimen Common Stock Certificate.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>(2)</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1377121/000119312516665762/d144462dex42.htm">Amended and Restated Investor Rights Agreement, by and among Protagonist Therapeutics,&nbsp;Inc. and the stockholders named
therein, dated July&nbsp;10, 2015.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>(3)</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1377121/000110465918049963/a18-18323_3ex4d1.htm">Form of Class&nbsp;A Common Stock Purchase Warrant</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>(3)</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1377121/000110465918049963/a18-18323_3ex4d2.htm">Form of Class&nbsp;B Common Stock Purchase Warrant</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>5.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2236589zex-5_1.htm">Opinion of Cooley&nbsp;LLP.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2236589zex-10_1.htm">Securities Purchase Agreement, by and among the Registrant and certain purchasers identified on the signature pages thereto.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>(3)</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1377121/000110465918049963/a18-18323_3ex4d3.htm">Form of Registration Rights Agreement</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>23.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2236589zex-23_1.htm">Consent of PricewaterhouseCoopers&nbsp;LLP, Independent Registered Public Accounting Firm.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>23.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2236589zex-5_1.htm">Consent of Cooley&nbsp;LLP is contained in Exhibit&nbsp;5.1 to this Registration Statement.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>24.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="#Sig">Power of Attorney is contained on the signature pages.</A></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Previously
filed as an exhibit to the Registrant's Current Report on Form&nbsp;8-K (File No.&nbsp;001-37852) filed with the Securities and Exchange Commission on
August&nbsp;16, 2016 and incorporated herein by reference.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Previously
filed as an exhibit to the Registrant's Registration Statement on Form&nbsp;S-1, as amended (File No.&nbsp;333-212476), filed with the Securities and
Exchange Commission on August&nbsp;1, 2016 and incorporated herein by reference.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Previously
filed as an exhibit to the Registrant's Current Report on Form&nbsp;8-K (File No.&nbsp;001-37852) filed with the Securities and Exchange Commission on
August&nbsp;7, 2018 and incorporated herein by reference.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><A
NAME="ja45601_item_17._undertakings"> </A>
<A NAME="toc_ja45601_5"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;17.&nbsp;&nbsp;&nbsp;&nbsp;Undertakings    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned registrants hereby undertakes: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;To
file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;to
include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of 1933; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;to
reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof)
which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of
securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may
be reflected in the form of prospectus filed with the Commission pursuant to Rule&nbsp;424(b) if, in the aggregate, the changes in volume and price </FONT></P>

</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=21,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=855464,FOLIO='II-2',FILE='DISK104:[18ZCV1.18ZCV45601]JA45601A.;9',USER='CHE108053',CD=';6-SEP-2018;15:38' -->
<A NAME="page_ja45601_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>represent
no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;to
include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such
information in the registration statement; </FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>provided, however</I></FONT><FONT SIZE=2>, that the undertakings set forth in paragraphs&nbsp;(i), (ii)&nbsp;and (iii)&nbsp;of this section do not apply if
the registration statement is on Form&nbsp;S-3, Form&nbsp;SF-3 or Form&nbsp;F-3 and the information required to be included in a post-effective amendment by those paragraphs is contained in
reports filed with or furnished to the Commission by the registrant pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in
the registration statement, or is contained in a form of prospectus filed pursuant to Rule&nbsp;424(b) that is part of the registration statement. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;That,
for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;That,
for the purpose of determining liability under the Securities Act of 1933 to any purchaser: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;Each
prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus
was deemed part of and included in the registration statement; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;Each
prospectus required to be filed pursuant to Rule&nbsp;424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule&nbsp;430B relating to
an offering made pursuant to
Rule&nbsp;415(a)(1)(i), (vii)&nbsp;or (x)&nbsp;for the purpose of providing the information required by Section&nbsp;10(a) of the Securities Act of 1933 shall be deemed to be part of and
included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering
described in the prospectus. As provided in Rule&nbsp;430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective
date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof. </FONT><FONT SIZE=2><I>Provided, however,</I></FONT><FONT SIZE=2> that no statement made in a registration statement or prospectus that is part of the registration
statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a
time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made
in any such document immediately prior to such effective date. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;That
for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant to Section&nbsp;13(a) or
Section&nbsp;15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section&nbsp;15(d) of the Securities Exchange
Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=22,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=305050,FOLIO='II-3',FILE='DISK104:[18ZCV1.18ZCV45601]JA45601A.;9',USER='CHE108053',CD=';6-SEP-2018;15:38' -->
<A NAME="page_ja45601_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant
pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as
expressed in the Act and is therefore unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a
director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with
the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=23,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=298892,FOLIO='II-4',FILE='DISK104:[18ZCV1.18ZCV45601]JA45601A.;9',USER='CHE108053',CD=';6-SEP-2018;15:38' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_jc45601_1_5"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="jc45601_signatures"> </A>
<A NAME="toc_jc45601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SIGNATURES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form&nbsp;S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Newark,
California, on September&nbsp;6, 2018. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="49%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="46%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><B>PROTAGONIST THERAPEUTICS,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>  By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;DINESH V. PATEL, PH.D.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Dinesh V. Patel, Ph.D.<BR></FONT> <FONT SIZE=2><I>President, Chief Executive Officer and Director</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="Sig"></A>POWER OF ATTORNEY  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Dinesh V. Patel and Thomas P.
O'Neil, his or her true and lawful agent, proxy and attorney-in-fact, each acting alone, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in
any and all capacities, to (i)&nbsp;act on, sign, and file with the SEC any and all amendments (including post-effective amendments) to this registration statement together with all schedules and
exhibits thereto, (ii)&nbsp;act on, sign and file such certificates, instruments, agreements and other documents as may be necessary or appropriate in connection therewith, (iii)&nbsp;act on and
file any supplement to any prospectus included in this registration statement or any such amendment or any subsequent registration statement filed pursuant to Rule&nbsp;462(b) under the Securities
Act, and (iv)&nbsp;take any and all actions which may be necessary or appropriate to be done, as fully for all intents and purposes as he or she might or could do in person, hereby approving,
ratifying and confirming all that such agent, proxy and attorney-in-fact or any of his substitutes may lawfully do or cause to be done by virtue thereof. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="37%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="37%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="112pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Signatures

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Date

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;DINESH V. PATEL, PH.D.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Dinesh V. Patel, Ph.D.</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>President, Chief Executive Officer and Director </FONT><FONT SIZE=2><I>(Principal Executive Officer)</I></FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>September&nbsp;6, 2018</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;THOMAS P. O'NEIL<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Thomas P. O'Neil</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Chief Financial Officer </FONT><FONT SIZE=2><I>(Principal Financial and Accounting Officer)</I></FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>September&nbsp;6, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;HAROLD E. SELICK, PH.D.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Harold E. Selick, Ph.D.</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>September&nbsp;6, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;BRYAN GIRAUDO<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Bryan Giraudo</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>September&nbsp;6, 2018</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=24,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=501864,FOLIO='II-5',FILE='DISK104:[18ZCV1.18ZCV45601]JC45601A.;17',USER='CHE108053',CD=';6-SEP-2018;15:38' -->
<A NAME="page_jc45601_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg45601a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="37%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="37%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="112pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Signatures

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Date

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;CHAITAN KHOSLA, PH.D.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Chaitan Khosla, Ph.D.</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>September&nbsp;6, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;SARAH NOONBERG, M.D., PH.D.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Sarah Noonberg, M.D., Ph.D.</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>September&nbsp;6, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;ARMEN SHANAFELT, PH.D.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Armen Shanafelt, Ph.D.</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>September&nbsp;6, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;WILLIAM D. WADDILL<BR>



<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> William D. Waddill</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>September&nbsp;6, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/S/ LEWIS T. "RUSTY" WILLIAMS,&nbsp;M.D.,&nbsp;PH.D.</FONT><FONT SIZE=2><BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Lewis T. "Rusty" Williams, M.D., Ph.D.</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>September&nbsp;6, 2018</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=25,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=12054,FOLIO='II-6',FILE='DISK104:[18ZCV1.18ZCV45601]JC45601A.;17',USER='CHE108053',CD=';6-SEP-2018;15:38' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>a2236589zex-5_1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 5.1</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="173" height="67" src="g230562kii001.jpg"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Kenneth L. Guernsey</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">+1 415 693 2091</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">kguernsey@cooley.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">September&nbsp;5, 2018</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Protagonist Therapeutics,&nbsp;Inc.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7707 Gateway Blvd., Suite&nbsp;140</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Newark, California 94560-1160</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 22.3pt;text-indent:-22.3pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Re:</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Registration Statement on Form&nbsp;S-3</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ladies and Gentlemen:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have acted as counsel to Protagonist Therapeutics,&nbsp;Inc., a Delaware corporation (the &#147;<b><i style="font-weight:bold;">Company</i></b>&#148;), in connection with the filing by the Company of a Registration Statement on Form&nbsp;S-3 (the &#147;<b><i style="font-weight:bold;">Registration Statement</i></b>&#148;) under the Securities Act of 1933, as amended, covering the resale by certain selling stockholders of up to 2,750,000 shares of Common Stock (the &#147;<b><i style="font-weight:bold;">Warrant Shares</i></b>&#148;) issuable upon the exercise of certain Class&nbsp;A and Class&nbsp;B warrants held by such selling stockholders (collectively, the &#147;<b><i style="font-weight:bold;">Warrants</i></b>&#148;) issued by the Company pursuant to that certain Securities Purchase Agreement, dated as of August&nbsp;6, 2018, by and among the Company and the purchasers named therein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with this opinion, we have examined and relied upon the Registration Statement and related prospectus included therein (the &#147;<b><i style="font-weight:bold;">Prospectus</i></b>&#148;), the Company&#146;s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, each as currently in effect, and the originals or copies certified to our satisfaction of such other records, documents, certificates, memoranda and other instruments as we deem necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness and authenticity of all documents submitted to us as originals and the conformity to originals of all documents submitted to us as copies thereof.&#160; As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently sought to verify such matters.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware.&#160; We express no opinion as to whether any particular laws other than those identified above are applicable to the subject matter hereof. We are not rendering any opinion as to compliance with any federal or state antifraud law, rule&nbsp;or regulation relating to securities, or to the sale or issuance thereof.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Warrant Shares, when issued and sold in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cooley LLP&#160;&#160; 101 California Street&#160;&#160; 5th Floor&#160;&#160; San Francisco, CA&#160;&#160; 94111-5800<br> t: (415) 693-2000&#160; f: (415) 693-2222&#160; cooley.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="2",CHK=735252,FOLIO='',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KI_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 08:05 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We hereby consent to the reference to our firm under the caption &#147;Legal Matters&#148; in the Prospectus included in the Registration Statement and to the filing of this opinion as an exhibit to the Registration Statement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Very truly yours,</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">COOLEY LLP</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Kenneth L. Guernsey</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Kenneth L. Guernsey</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="23056-2-KI_PB_2_080500_7117"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="2",CHK=725666,FOLIO='2',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KI_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 08:05 2018' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>a2236589zex-10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.1</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECURITIES PURCHASE AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Securities Purchase Agreement (this &#147;<u>Agreement</u>&#148;) is dated as of August&nbsp;6, 2018 (the &#147;<u>Effective Date</u>&#148;), between Protagonist Therapeutics,&nbsp;Inc., a Delaware corporation (the &#147;<u>Company</u>&#148;), and each purchaser identified on the signature pages&nbsp;hereto (each, including its successors and assigns, a &#147;<u>Purchaser</u>&#148; and collectively the &#147;<u>Purchasers</u>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to (i)&nbsp;an effective registration statement under the Securities Act of 1933, as amended (the &#147;<u>Securities Act</u>&#148;) as to the Shares and (ii)&nbsp;an exemption from the registration requirements of Section&nbsp;5 of the Securities Act contained in Section&nbsp;4(a)(2)&nbsp;thereof and/or Regulation D thereunder as to the Warrants, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, on the Closing Date, the Company and the Purchasers will execute and deliver a Registration Rights Agreement in the form attached hereto as <u>Exhibit&nbsp;C</u> (the &#147;<u>Registration Rights Agreement</u>&#148;), pursuant to which, among other things, the Company will agree to provide certain registration rights with respect to the Warrants and the Warrant Shares under the Securities Act and the rules&nbsp;and regulations promulgated thereunder and applicable state securities laws.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NOW, THEREFORE,&nbsp;IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;I.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">DEFINITIONS</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1 <u>Definitions</u>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section&nbsp;1.1:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Action</u>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(j).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Affiliate</u>&#148; has the meaning set forth in Rule&nbsp;12b-2 of the rules&nbsp;and regulations promulgated under the Exchange Act; provided, however, that for purposes of this Agreement, the Purchasers and their Affiliates, on the one hand, and the Company and its Affiliates, on the other, shall not be deemed to be &#147;Affiliates&#148; of one another.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Board of Directors</u>&#148; means the board of directors of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Business Day</u>&#148; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Closing</u>&#148; means the closing of the purchase and sale of the Securities pursuant to Section&nbsp;2.1.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Closing Date</u>&#148; means the second Trading Day following the date hereof.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Commission</u>&#148; means the United States Securities and Exchange Commission.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Common Stock</u>&#148; means the common stock of the Company, par value $0.00001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Company Counsel</u>&#148; means Cooley LLP.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Evaluation Date</u>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(s).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Exchange Act</u>&#148; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">1<a name="23056-2-KS-01_PB_1_072955_768"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=315108,FOLIO='1',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-01_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 07:31 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>FCPA</u>&#148; means the Foreign Corrupt Practices Act of 1977, as amended.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>FDA</u>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(ee).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>GAAP</u>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(h).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Intellectual Property Rights</u>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(p).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Liens</u>&#148; means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Material Adverse Effect</u>&#148; shall have the meaning assigned to such term in Section&nbsp;3.1(b).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Material Permits</u>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(n).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Per Share Purchase Price</u>&#148; equals $8.00, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Person</u>&#148; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Proceeding</u>&#148; means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Prospectus</u>&#148; means the final prospectus filed for the Registration Statement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Prospectus Supplement</u>&#148; means the supplement to the Prospectus complying with Rule&nbsp;424(b)&nbsp;of the Securities Act that is filed with the Commission and made available to each Purchaser at the Closing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Purchaser Party</u>&#148; shall have the meaning ascribed to such term in Section&nbsp;4.5.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Registration Statement</u>&#148; means the effective registration statement with Commission file No.&nbsp;333-220314 which registers the sale of the Shares to the Purchasers.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Required Approvals</u>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(e).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Rule&nbsp;144</u>&#148; means Rule&nbsp;144 promulgated by the Commission pursuant to the Securities Act, as such Rule&nbsp;may be amended or interpreted from time to time, or any similar rule&nbsp;or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Rule&nbsp;424</u>&#148; means Rule&nbsp;424 promulgated by the Commission pursuant to the Securities Act, as such Rule&nbsp;may be amended or interpreted from time to time, or any similar rule&nbsp;or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>SEC Reports</u>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(h).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Securities</u>&#148; means the Shares, the Warrants and the Warrant Shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Securities Act</u>&#148; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Shares</u>&#148; means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Short Sales</u>&#148; means all &#147;short sales&#148; as defined in Rule&nbsp;200 of Regulation SHO under the Exchange Act (but shall not be deemed to include locating and/or borrowing shares of Common Stock).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Subscription Amount</u>&#148; means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants purchased hereunder as specified below such Purchaser&#146;s name on the signature page&nbsp;of this</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="23056-2-KS-01_PB_2_073002_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=840043,FOLIO='2',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-01_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 07:31 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Agreement and next to the heading &#147;Subscription Amount,&#148; in United States dollars and in immediately available funds.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Subsidiary</u>&#148; means any subsidiary of the Company as set forth in the SEC Reports, and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Trading Day</u>&#148; means a day on which the principal Trading Market is open for trading.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Trading Market</u>&#148; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange (or any successors to any of the foregoing).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Transaction Documents</u>&#148; means this Agreement, the Warrants, the Registration Rights Agreement and any other documents or agreements executed in connection with the transactions contemplated hereunder.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Transfer Agent</u>&#148; means </font>American Stock Transfer&nbsp;&amp; Trust Company, LLC, 6201 15th Avenue Brooklyn, New York 11219.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Warrants</u>&#148; means, collectively, (i)&nbsp;the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section&nbsp;2.2(a)&nbsp;hereof, in the form of <u>Exhibit&nbsp;A</u> attached hereto (the &#147;<u>Class&nbsp;A Warrants</u>&#148;) and (ii)&nbsp;the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section&nbsp;2.2(a)&nbsp;hereof, in the form of <u>Exhibit&nbsp;B </u>attached hereto (the &#147;<u>Class&nbsp;B Warrants</u>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Warrant Shares</u>&#148; means the shares of Common Stock issuable upon exercise of the Warrants.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;II.</font></b><br> PURCHASE AND SALE</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1 <u>Closing</u>. On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution and delivery of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase, up to an aggregate of $22,000,000 of Shares and Warrants. Each Purchaser&#146;s Subscription Amount as set forth on the signature page&nbsp;hereto executed by such Purchaser shall be made by wire transfer to a bank account designated by the Company.&#160; The Company shall deliver to each Purchaser its respective Shares and the Warrants as determined pursuant to Section&nbsp;2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section&nbsp;2.2 as deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices of Cooley or such other location as the parties shall mutually agree.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.2 <u>Deliveries</u>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&nbsp;On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)&nbsp;this Agreement duly executed by the Company;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)&nbsp;a legal opinion of Company Counsel, in form and substance reasonably satisfactory to the Purchasers;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)&nbsp;a Class&nbsp;A Warrant in the form of <u>Exhibit&nbsp;A</u> attached hereto registered in name of such Purchaser to purchase up to a number of shares of Common Stock equal to 50% of such Purchaser&#146;s Shares, with an exercise price equal to $10.00, subject to adjustment therein;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="23056-2-KS-01_PB_3_073010_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=682560,FOLIO='3',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-01_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 07:31 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)&nbsp;a Class&nbsp;B Warrant in the form of <u>Exhibit&nbsp;B</u> attached hereto registered in name of such Purchaser to purchase up to a number of shares of Common Stock equal to 50% of such Purchaser&#146;s Shares, with an exercise price equal to $15.00, subject to adjustment therein; and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)&nbsp;subject to the last sentence of Section&nbsp;2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver via The Depository Trust Company Deposit or Withdrawal at Custodian system (&#147;<u>DWAC</u>&#148;) Shares equal to such Purchaser&#146;s Subscription Amount divided by the Per Share Purchase Price, registered in the name of such Purchaser;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)&nbsp;the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule&nbsp;172 under the Securities Act).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&nbsp;On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company, the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)&nbsp;this Agreement duly executed by such Purchaser; and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)&nbsp;such Purchaser&#146;s Subscription Amount, which shall be made available for settlement with the Company or its designee.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.3 <u>Closing Conditions</u>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&nbsp;The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)&nbsp;the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which case they shall be accurate as of such date);</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)&nbsp;all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)&nbsp;the delivery by each Purchaser of the items set forth in Section&nbsp;2.2(b)&nbsp;of this Agreement; and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)&nbsp;a minimum of 2,500,000 Shares must be sold at the Closing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&nbsp;The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)&nbsp;the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein in which case they shall be accurate as of such date);</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)&nbsp;all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)&nbsp;the delivery by the Company of the items set forth in Section&nbsp;2.2(a)&nbsp;of this Agreement; and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)&nbsp; from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&#146;s principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="23056-2-KS-01_PB_4_073017_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=605847,FOLIO='4',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-01_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 07:31 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">have been established on securities whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;III.</font></b><br> REPRESENTATIONS AND WARRANTIES</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1 <u>Representations and Warranties of the Company</u>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&nbsp;<u>Subsidiaries</u>. All of the direct and indirect subsidiaries of the Company are set forth in the SEC Reports. The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&nbsp;<u>Organization and Qualification</u>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in a material adverse effect on the results of operations, assets, business or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole (a &#147;<u>Material Adverse Effect</u>&#148;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)&nbsp;<u>Authorization; Enforcement</u>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company&#146;s stockholders in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i)&nbsp;as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="23056-2-KS-01_PB_5_073046_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=276212,FOLIO='5',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-01_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 07:31 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">general application affecting enforcement of creditors&#146; rights generally, (ii)&nbsp;as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by applicable law.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&nbsp;<u>No Conflicts</u>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will not (i)&nbsp;conflict with or violate any provision of the Company&#146;s or any Subsidiary&#146;s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii)&nbsp;conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii)&nbsp;subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii)&nbsp;and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)&nbsp;<u>Filings, Consents and Approvals</u>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i)&nbsp;the filings required pursuant to Section&nbsp;4.3 of this Agreement, (ii)&nbsp;the filing with the Commission of the Prospectus Supplement, (iii)&nbsp;application(s)&nbsp;to each applicable Trading Market for the listing of the Shares and Warrant Shares for trading thereon in the time and manner required thereby, and (iv)&nbsp;the filing with the Commission of such filings as are required to be made under applicable state securities laws (collectively, the &#147;<u>Required Approvals</u>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)&nbsp;<u>Issuance of the Securities; Registration</u>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Warrant Shares, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant to this Agreement and the Warrants. The Company has prepared and filed the Registration Statement in conformity with the requirements of the Securities Act, which became effective on October&nbsp;5, 2017, including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement. The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules&nbsp;and regulations of the Commission, shall file the Prospectus with the Commission pursuant to Rule&nbsp;424(b). At the time the Registration Statement and any amendments thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="23056-2-KS-01_PB_6_073052_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=698561,FOLIO='6',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-01_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 07:31 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at time the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The Company was at the time of the filing of the Registration Statement eligible to use Form&nbsp;S-3. The Company is eligible to use Form&nbsp;S-3 under the Securities Act and it meets the transaction requirements with respect to the aggregate market value of securities being sold pursuant to this offering and during the twelve (12) months prior to this offering, as set forth in General Instruction I.B.6 of Form&nbsp;S-3.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)&nbsp;<u>Capitalization</u>. As of the date hereof, there are issued and outstanding 21,218,169 shares of Common Stock and no shares of Preferred Stock.&nbsp;&nbsp;As of the date hereof, the Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than securities issued or issuable pursuant to existing Company equity incentive, inducement, stock option or stock purchase plans or agreements disclosed in the SEC Reports.&nbsp;&nbsp;No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents.&nbsp;&nbsp;Other than (i)&nbsp;securities issued or issuable pursuant to existing Company equity incentive, stock option or stock purchase plans or agreements disclosed in the SEC Reports or (ii)&nbsp;as set forth in the Company&#146;s most recently filed periodic report under the Exchange Act, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock.&nbsp;&nbsp;All of the outstanding shares of capital stock of the Company are validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)&nbsp;<u>SEC Reports; Financial Statements</u>. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and the Prospectus Supplement, being collectively referred to herein as the &#147;<u>SEC Reports</u>&#148;) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The Company has never been an issuer subject to Rule&nbsp;144(i)&nbsp;under the Securities Act. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules&nbsp;and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&#147;<u>GAAP</u>&#148;), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="23056-2-KS-01_PB_7_073059_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=669073,FOLIO='7',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-01_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 07:31 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)&nbsp;<u>Material Changes; Undisclosed Events, Liabilities or Developments</u>. Since March&nbsp;31, 2018, except as specifically disclosed in SEC Reports (i)&nbsp;there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii)&nbsp;the Company has not incurred any liabilities (contingent or otherwise) other than (A)&nbsp;trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B)&nbsp;liabilities not required to be reflected in the Company&#146;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii)&nbsp;the Company has not altered its method of accounting, (iv)&nbsp;the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v)&nbsp;the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment of information.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)&nbsp;<u>Litigation</u>. Except as disclosed in the SEC Reports, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &#147;<u>Action</u>&#148;) which (i)&nbsp;adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii)&nbsp;could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(k)&nbsp;<u>Labor Relations</u>. No labor dispute with the employees of the Company or its Subsidiaries exists or, to the knowledge of the Company, is imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its or its Subsidiaries&#146; principal suppliers, manufacturers, customers or contractors, which, in either case, would result in a Material Adverse Effect.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(l)&nbsp;<u>Compliance</u>. Neither the Company nor any Subsidiary: (i)&nbsp;is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii)&nbsp;is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii)&nbsp;is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(m)&nbsp;<u>Environmental Laws</u>. Except as would not, singly or in the aggregate, result in a</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="23056-2-KS-01_PB_8_073107_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=304083,FOLIO='8',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-01_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 07:31 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Material Adverse Effect, (i)&nbsp;neither the Company nor any Subsidiary is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule&nbsp;of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products, asbestos-containing materials or mold (collectively, &#147;<u>Hazardous Materials</u>&#148;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &#147;<u>Environmental Laws</u>&#148;), (ii)&nbsp;the Company and its Subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with their requirements, (iii)&nbsp;there are no pending or, to the knowledge of the Company threatened, administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any Subsidiary and (iv)&nbsp;there are no events or circumstances that would reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or any arbitrator, court, governmental body, regulatory body, administrative agency or other authority, body or agency having jurisdiction over the Company or its Subsidiaries or any of their respective properties, assets or operations, against or affecting the Company or any Subsidiary relating to Hazardous Materials or any Environmental Laws.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(n)&nbsp;<u>Regulatory Permits</u>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&#147;<u>Material Permits</u>&#148;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(o)&nbsp;<u>Title to Assets</u>. The Company and its Subsidiaries have good and marketable title to all real property owned by them and good title to all other properties owned by them, in each case, free and clear of all mortgages, pledges, liens, security interests, claims, restrictions or encumbrances of any kind except such as do not, singly or in the aggregate, materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company or its Subsidiaries; and all of the leases and subleases material to the business of the Company and its Subsidiaries, considered as one enterprise, are in full force and effect, and neither the Company nor any such Subsidiary has any notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company or any Subsidiary under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company or such Subsidiary to the continued possession of the leased or subleased premises under any such lease or sublease.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(p)&nbsp;<u>Intellectual Property</u>. Except as disclosed in the SEC Reports, the Company and its Subsidiaries own, or possess sufficient rights to use, all trademarks, service marks, trade names (including all goodwill associated with the foregoing), patent rights, copyrights, domain names, licenses, approvals, trade secrets, inventions, technology, know-how and other intellectual property and similar rights, including registrations and applications for registration thereof (collectively, &#147;<u>Intellectual Property Rights</u>&#148;) used in, or necessary for the conduct of the business now conducted or proposed to be conducted by the Company or its Subsidiaries. Except as disclosed in the SEC Reports, (A)&nbsp;To the Company&#146;s knowledge, there are no rights of third parties to any of the Intellectual Property Rights owned by the Company or its Subsidiaries, (B)&nbsp;to the Company&#146;s knowledge, there is no infringement, misappropriation, breach, default or other violation by any</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="23056-2-KS-01_PB_9_073114_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=452188,FOLIO='9',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-01_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 07:31 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">third party of any of the Intellectual Property Rights of the Company or any of its Subsidiaries, (C)&nbsp;the Company and its Subsidiaries have taken reasonable steps in accordance with normal industry practice to maintain the confidentiality of all Intellectual Property Rights the value of which to the Company or any Subsidiary is contingent upon maintaining the confidentiality thereof, (D)&nbsp;the Company is not obligated to pay a material royalty, grant a license to, or provide other material consideration to any third party in connection with the Intellectual Property Rights, and (E)&nbsp;to the Company&#146;s knowledge, all Intellectual Property Rights owned by or exclusively licensed to the Company or any of its Subsidiaries are valid and enforceable. To the Company&#146;s knowledge, neither the Company nor any of its Subsidiaries has materially infringed, misappropriated or otherwise violated the Intellectual Property Rights of any third party, and neither the manufacture of, nor the use or sale of, any of the Company&#146;s product candidates, would materially infringe or otherwise violate the Intellectual Property Rights of any third party. There is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by any third party (i)&nbsp;challenging the Company&#146;s or any of its Subsidiaries&#146; rights in or to, or alleging the violation of any of the terms of, any of their Intellectual Property Rights, (ii)&nbsp;challenging the validity, enforceability or scope of any Intellectual Property Rights owned by or exclusively licensed to the Company or any of its Subsidiaries, or (iii)&nbsp;alleging that the Company or any of its Subsidiaries has infringed, misappropriated or otherwise violated or conflicted with any Intellectual Property Rights of any third party, and in the case of each of (i), (ii)&nbsp;and (iii)&nbsp;above, the Company is unaware of any fact which would form a reasonable basis for any such action, suit, proceeding or claim.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(q)&nbsp;<u>Insurance</u>. The Company and its Subsidiaries carry or are entitled to the benefits of insurance, with financially sound and reputable insurers, in such amounts and covering such risks as is generally maintained by companies of established repute engaged in the same or similar business, and all such insurance is in full force and effect.&#160; The Company has no reason to believe that it or its Subsidiaries will not be able (A)&nbsp;to renew its existing insurance coverage as and when such policies expire or (B)&nbsp;to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result in a Material Adverse Effect.&#160; None of the Company nor any of its Subsidiaries has been denied any insurance coverage which it has sought or for which it has applied.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(r)&nbsp;<u>Transactions With Affiliates and Employees</u>. Except as set forth in the SEC Reports, none of the officers or directors of the Company and, to the Company&#146;s knowledge, none of the employees of the Company is presently a party to any transaction with the Company (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the Company&#146;s knowledge, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner, other than for (i)&nbsp;payment of salary or consulting fees for services rendered, (ii)&nbsp;reimbursement for expenses incurred on behalf of the Company and (iii)&nbsp;other employee benefits, including stock option agreements under any stock option plan of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(s)&nbsp;<u>Sarbanes-Oxley; Internal Accounting Controls</u>. The Company and the Subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules&nbsp;and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations, (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization, and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="23056-2-KS-01_PB_10_073122_8146"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=32029,FOLIO='10',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-01_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 07:31 2018' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#146;s rules&nbsp;and forms. The Company&#146;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the &#147;<u>Evaluation Date</u>&#148;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(t)&nbsp;<u>Certain Fees</u>. Except as set forth in the Prospectus Supplement, no brokerage or finder&#146;s fees or commissions are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section&nbsp;that may be due in connection with the transactions contemplated by the Transaction Documents.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(u)&nbsp;<u>Investment Company</u>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be or be an Affiliate of, an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become an &#147;investment company&#148; subject to registration under the Investment Company Act of 1940, as amended.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)&nbsp;<u>Registration Rights</u>. Other than pursuant to Second Amended and Restated Investor Rights Agreement, dated as of July&nbsp;10, 2015, by and among the Company and certain of its stockholders, no Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(w)&nbsp;<u>Listing and Maintenance Requirements</u>. The Common Stock is registered pursuant to Section&nbsp;12(b)&nbsp;or 12(g)&nbsp;of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. The Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(x)&nbsp;<u>Disclosure</u>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">11<a name="23056-2-KS-03_PB_11_073157_3272"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=415221,FOLIO='11',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-03_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 07:33 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section&nbsp;3.2 hereof.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(y)&nbsp;<u>No Integrated Offering</u>. Assuming the accuracy of the Purchasers&#146; representations and warranties set forth in Section&nbsp;3.2, neither the Company nor any Person acting on its behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of (i)&nbsp;the Securities Act which would require the registration of the Warrants or Warrant Shares under the Securities Act, or (ii)&nbsp;any applicable stockholder approval provisions of any Trading Market on which any of the securities of the Company are listed or designated.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(z)&nbsp;<u>Tax Status</u>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the Company and its Subsidiaries each (i)&nbsp;has made or filed all United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)&nbsp;has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations and (iii)&nbsp;has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(aa) <u>Foreign Corrupt Practices</u>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person acting on behalf of the Company or any Subsidiary, has (i)&nbsp;directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii)&nbsp;made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii)&nbsp;failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv)&nbsp;violated in any material respect any provision of FCPA.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(bb) <u>Accountants</u>. The Company&#146;s accounting firm is set forth in the SEC Reports. To the knowledge and belief of the Company, such accounting firm (i)&nbsp;is a registered public accounting firm as required by the Exchange Act and (ii)&nbsp;shall express its opinion with respect to the financial statements to be included in the Company&#146;s Annual Report on Form&nbsp;10-K for the fiscal year ending December&nbsp;31, 2018.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(cc) <u>Acknowledgment Regarding Purchasers&#146; Purchase of Securities</u>. The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm&#146;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">12<a name="23056-2-KS-03_PB_12_073203_7091"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=846169,FOLIO='12',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-03_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 07:33 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers&#146; purchase of the Securities. The Company further represents to each Purchaser that the Company&#146;s decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(dd) <u>Regulation M Compliance</u>. The Company has not, and to its knowledge no one acting on its behalf has, (i)&nbsp;taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii)&nbsp;sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities, or (iii)&nbsp;paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ee) <u>FDA</u>. The Company and its Subsidiaries: (A)&nbsp;have operated and currently operate their respective businesses in compliance in all material respects with applicable provisions of the Health Care Laws (as defined below) of the U.S. Food and Drug Administration (the &#147;<u>FDA</u>&#148;) and any comparable foreign regulatory authority to which they are subject (collectively, the &#147;<u>Applicable Regulatory Authorities</u>&#148;) applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, storage, import, export or disposal of any of the Company&#146;s or its Subsidiaries&#146; product candidates or any product manufactured or distributed by the Company and its Subsidiaries; (B)&nbsp;have not received any FDA Form&nbsp;483, written notice of adverse finding, warning letter, untitled letter or other correspondence or written notice from any court or arbitrator or governmental or regulatory authority alleging or asserting non-compliance with (i)&nbsp;any Health Care Laws or (ii)&nbsp;or any licenses, certificates, approvals, clearances, exemptions, authorizations, permits and supplements or amendments thereto required by any such Health Care Laws (&#147;<u>Regulatory Authorizations</u>&#148;); (C)&nbsp;possesses all Regulatory Authorizations and such Regulatory Authorizations are valid and in full force and effect and the Company is not in violation, in any material respect, of any term of any such Regulatory Authorizations; (D)&nbsp;has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the Applicable Regulatory Authorities or any other third party alleging that any product operation or activity is in material violation of any Health Care Laws or Regulatory Authorizations and has no knowledge that the Applicable Regulatory Authorities or&#160; any other third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (E)&nbsp;has not received notice that any of the Applicable Regulatory Authorities has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Regulatory Authorizations and has no knowledge that any of the Applicable Regulatory Authorities is considering such action; and (F)&nbsp;has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws or Regulatory Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were materially corrected or supplemented by a subsequent submission).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The term &#147;Health Care Laws&#148; means Title XVIII of the Social Security Act, 42 U.S.C. &#167;&#167; 1395-1395hhh (the Medicare statute); Title XIX of the Social Security Act, 42 U.S.C. &#167;&#167; 1396-1396v (the Medicaid statute); the Federal Anti-Kickback Statute, 42 U.S.C. &#167; 1320a-7b(b); the civil False Claims Act, 31 U.S.C. &#167;&#167; 3729 et seq.; the criminal False Claims Act 42 U.S.C. 1320a-7b(a); any criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287 and the health care fraud criminal provisions under the Health Insurance Portability and Accountability Act of 1996, 42 U.S.C. &#167;&#167; 1320d et seq., (&#147;<u>HIPAA</u>&#148;); the Civil Monetary Penalties Law, 42 U.S.C. &#167;&#167; 1320a-7a and 1320a-7b; the Physician Payments Sunshine</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">13<a name="23056-2-KS-03_PB_13_073214_455"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=1025622,FOLIO='13',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-03_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 07:33 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Act, 42 U.S.C. &#167; 1320a-7h; the Exclusion Laws, 42 U.S.C. &#167; 1320a-7; HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, 42 U.S.C. &#167;&#167; 17921 et seq.; the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. &#167;&#167; 301 et seq.; the Public Health Service Act, 42 U.S.C. &#167;&#167; 201 et seq.; the regulations promulgated pursuant to such laws; and any similar federal, state and local laws and regulations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ff) <u>Office of Foreign Assets Control</u>. Neither the Company nor any Subsidiary nor, to the Company&#146;s knowledge, any director, officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(gg) <u>U.S. Real Property Holding Corporation</u>. The Company is not and has never been a U.S. real property holding corporation within the meaning of Section&nbsp;897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&#146;s request.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(hh) <u>Money Laundering</u>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules&nbsp;and regulations thereunder (collectively, the &#147;<u>Money Laundering Laws</u>&#148;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)&nbsp;<u>Private Placement</u>. Assuming the accuracy of the Purchasers&#146; representations and warranties set forth in Section&nbsp;3.2, no registration under the Securities Act is required for the offer and sale of the Warrants or the Warrant Shares by the Company to the Purchasers as contemplated hereby.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(jj) <u>No General Solicitation</u>. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Warrant or Warrant Shares by any form of general solicitation or general advertising. The Company has offered the Warrants and Warrant Shares for sale only to the Purchasers and certain other &#147;accredited investors&#148; within the meaning of Rule&nbsp;501 under the Securities Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(kk) <u>No Disqualification Events</u>. With respect to the Warrant and Warrant Shares to be offered and sold hereunder in reliance on Rule&nbsp;506 under the Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company&#146;s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule&nbsp;405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an &#147;<u>Issuer Covered Person</u>&#148;) is subject to any of the &#147;Bad Actor&#148; disqualifications described in Rule&nbsp;506(d)(1)(i)&nbsp;to (viii)&nbsp;under the Securities Act (a &#147;<u>Disqualification Event</u>&#148;), except for a Disqualification Event covered by Rule&nbsp;506(d)(2)&nbsp;or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule&nbsp;506(e), and has furnished to the Purchasers a copy of any disclosures provided thereunder.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.2 <u>Representations and Warranties of the Purchasers</u>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate as of such date):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 21.0pt;text-indent:51.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&nbsp;<u>Organization; Authority</u>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction of its</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">14<a name="23056-2-KS-03_PB_14_073223_4141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=14,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=429841,FOLIO='14',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-03_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 07:33 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 21.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">incorporation or formation with full right, corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i)&nbsp;as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#146; rights generally, (ii)&nbsp;as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by applicable law.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 21.0pt;text-indent:51.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&nbsp;<u>Understandings or Arrangements</u>. Such Purchaser is acquiring the Warrants and Warrants Shares as principal for its own account and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Warrants and Warrant Shares (this representation and warranty not limiting such Purchaser&#146;s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Warrant and Warrant Shares hereunder in the ordinary course of its business. Such Purchaser understands that the Warrants and the Warrant Shares are &#147;restricted securities&#148; and have not been registered under the Securities Act or any applicable state securities law and is acquiring such Securities as principal for his, her or its own account and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities in violation of the Securities Act or any applicable state securities law (this representation and warranty not limiting such Purchaser&#146;s right to sell such Securities pursuant to a registration statement or otherwise in compliance with applicable federal and state securities laws).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 21.0pt;text-indent:51.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)&nbsp;<u>Purchaser Status</u>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which it exercises any Warrants, it will be an &#147;accredited investor&#148; as defined in Rule&nbsp;501(a)(1), (a)(2), (a)(3), (a)(7)&nbsp;or (a)(8)&nbsp;under the Securities Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 21.0pt;text-indent:51.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&nbsp;<u>Experience of Such Purchaser</u>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 21.0pt;text-indent:51.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)&nbsp;<u>Access to Information</u>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i)&nbsp;the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii)&nbsp;access to information about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii)&nbsp;the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">15<a name="23056-2-KS-03_PB_15_073231_8627"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=15,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=6351,FOLIO='15',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-03_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 07:33 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 21.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">investment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 21.0pt;text-indent:51.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)&nbsp;<u>Certain Transactions and Confidentiality</u>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#146;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#146;s assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser&#146;s representatives, including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 21.0pt;text-indent:51.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)&nbsp;<u>General Solicitation</u>. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company acknowledges and agrees that the representations contained in this Section&nbsp;3.2 shall not modify, amend or affect such Purchaser&#146;s right to rely on the Company&#146;s representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;IV.</font></b><br> OTHER AGREEMENTS OF THE PARTIES</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1 <u>Legends</u>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&nbsp;The Warrants and Warrant Shares may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Warrants or Warrant Shares other than pursuant to an effective registration statement or Rule&nbsp;144, to the Company or to an Affiliate of a Purchaser or in connection with a pledge as contemplated in Section&nbsp;4.1(b), the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Warrant under the Securities Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&nbsp; The Purchasers agree to the imprinting, so long as is required by this Section&nbsp;4.1, of a legend on any of the Warrants or Warrant Shares in the following form:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">16<a name="23056-2-KS-03_PB_16_073238_7906"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=16,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=237297,FOLIO='16',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-03_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 07:33 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;SECURITIES ACT&#148;), AND, ACCORDINGLY, MAY&nbsp;NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY&nbsp;BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &#147;ACCREDITED INVESTOR&#148; AS DEFINED IN RULE 501(a)&nbsp;UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant a security interest in some or all of the Warrants or Warrant Shares to a financial institution that is an &#147;accredited investor&#148; as defined in Rule&nbsp;501(a)&nbsp;under the Securities Act and, if required under the terms of such arrangement, such Purchaser may transfer pledged or secured Warrants or Warrant Shares to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge. At the appropriate Purchaser&#146;s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of Warrants and Warrant Shares may reasonably request in connection with a pledge or transfer of the Warrants or Warrant Shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2 <u>Integration</u>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section&nbsp;2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require the registration under the Securities Act of the sale of the Warrants or Warrant Shares or that would be integrated with the offer or sale of the Securities for purposes of the rules&nbsp;and regulations of any Trading Market such that it would require stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.3 <u>Securities Laws Disclosure; Publicity</u>. The Company shall (a)&nbsp;by 9:00 a.m.&nbsp;(New York City time) on the date hereof, issue a press release disclosing the material terms of the transactions contemplated hereby, and (b)&nbsp;file a Current Report on Form&nbsp;8-K with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">17<a name="23056-2-KS-03_PB_17_073245_3736"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=17,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=87008,FOLIO='17',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-03_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 07:33 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a)&nbsp;as required by federal securities law in connection with the filing of final Transaction Documents with the Commission and (b)&nbsp;to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under this clause (b).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.4 <u>Non-Public Information</u>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, which shall be disclosed pursuant to Section&nbsp;4.3, the Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the receipt of such information and agreed with the Company to keep such information confidential. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company delivers any material, non-public information to a Purchaser without such Purchaser&#146;s consent, the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form&nbsp;8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.5 <u>Indemnification of Purchasers</u>. Subject to the provisions of this Section&nbsp;4.5, the Company will indemnify and hold each Purchaser and its directors, officers, stockholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section&nbsp;15 of the Securities Act and Section&nbsp;20 of the Exchange Act), and the directors, officers, stockholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a &#147;<u>Purchaser Party</u>&#148;) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys&#146; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a)&nbsp;any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b)&nbsp;any action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless such action is based upon a breach of such Purchaser Party&#146;s representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence, willful misconduct or malfeasance). If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (x)&nbsp;the employment thereof has been specifically authorized by the Company in writing, (y)&nbsp;the Company has failed after a reasonable period of</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">18<a name="23056-2-KS-03_PB_18_073253_9621"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=18,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=813197,FOLIO='18',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-03_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 07:33 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">time to assume such defense and to employ counsel or (z)&nbsp;in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (1)&nbsp;for any settlement by a Purchaser Party effected without the Company&#146;s prior written consent, which shall not be unreasonably withheld or delayed; or (2)&nbsp;to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&#146;s breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification required by this Section&nbsp;4.5 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.6 <u>Reservation of Common Stock</u>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.7 <u>Listing of Common Stock</u>. The Company hereby agrees to use reasonable best efforts to maintain the listing or quotation of the Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in such application all of the Shares and Warrant Shares, and will take such other action as is necessary to cause all of the Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company&#146;s reporting, filing and other obligations under the bylaws or rules&nbsp;of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.8 <u>Equal Treatment of Purchasers</u>. No consideration (including any modification of any Transaction Document) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.9 <u>Certain Transactions and Confidentiality</u>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short Sales of any of the Company&#146;s securities during the period commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section&nbsp;4.3. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section&nbsp;4.3, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included in the Disclosure Schedules. Notwithstanding the foregoing and notwithstanding anything contained in this</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">19<a name="23056-2-KS-03_PB_19_073300_8715"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=19,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=608161,FOLIO='19',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-03_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 07:33 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Agreement to the contrary, the Company expressly acknowledges and agrees that (i)&nbsp;no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section&nbsp;4.3, (ii)&nbsp;no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section&nbsp;4.3 and (iii)&nbsp;no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company or its Subsidiaries after the issuance of the initial press release as described in Section&nbsp;4.3. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#146;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#146;s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.10 <u>Exercise Procedures</u>. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required of the Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with the terms, conditions and time periods set forth in the Transaction Documents.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.11 <u>Form&nbsp;D; Blue Sky Filings</u>. The Company agrees to timely file a Form&nbsp;D with respect to the Warrant and Warrant Shares as required under Regulation D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Warrant and Warrant Shares for, sale to the Purchasers at the Closing under applicable securities or &#147;Blue Sky&#148; laws of the states of the United States, and shall provide evidence of such actions promptly upon request of any Purchaser.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;V.</font></b><br> MISCELLANEOUS</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1 <u>Termination</u>. This Agreement may be terminated by any Purchaser, as to such Purchaser&#146;s obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been consummated within ten business days following the Effective Date; <u>provided</u>, <u>however</u>, that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2 <u>Fees and Expenses</u>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement, <i>provided</i>, <i>that</i>, at the Closing, the Company shall pay the reasonable fees and expenses of Gibson, Dunn&nbsp;&amp; Crutcher LLP, counsel for the lead Purchaser, in an amount not to exceed $25,000 in the aggregate. The Company shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.3 <u>Entire Agreement</u>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">20<a name="23056-2-KS-03_PB_20_073308_563"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=20,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=818460,FOLIO='20',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-03_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 07:33 2018' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.4 <u>Notices</u>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a)&nbsp;the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages&nbsp;attached hereto at or prior to 5:30 p.m.&nbsp;(New York City time) on a Trading Day, (b)&nbsp;the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages&nbsp;attached hereto on a day that is not a Trading Day or later than 5:30 p.m.&nbsp;(New York City time) on any Trading Day, (c)&nbsp;the second (2</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">nd</font>) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d)&nbsp;upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages&nbsp;attached hereto. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form&nbsp;8-K.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.5 <u>Amendments; Waivers</u>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and Purchasers which purchased a majority in interest of the Shares based on the initial Subscription Amounts hereunder or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected Purchaser, Any amendment effected in accordance with accordance with this Section&nbsp;5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.6 <u>Headings</u>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.7 <u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction Documents that apply to the &#147;Purchasers.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.8 <u>No Third-Party Beneficiaries</u>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section&nbsp;4.5.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.9 <u>Governing Law</u>. This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of Delaware without regard to the choice of law principles thereof. Each of the parties hereto irrevocably submits to the exclusive jurisdiction of the state and federal courts located in the State of Delaware for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated hereby. Service of process in connection with any</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">21<a name="23056-2-KS-05_PB_21_073349_6231"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=21,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=1022299,FOLIO='21',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-05_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 08:07 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Agreement. Each of the parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court. Each party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.10 <u>Survival</u>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.11 <u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a &#147;.pdf&#148; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &#147;.pdf&#148; signature page&nbsp;were an original thereof.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.12 <u>Severability</u>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.13 <u>Replacement of Securities</u>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.14 <u>Remedies</u>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would be adequate.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.15 <u>Independent Nature of Purchasers&#146; Obligations and Rights</u>. The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">22<a name="23056-2-KS-05_PB_22_073355_9497"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=22,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=271755,FOLIO='22',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-05_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 08:07 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchaser to be joined as an additional party in any Proceeding for such purpose. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.16 <u>Liquidated Damages</u>. The Company&#146;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts are due and payable shall have been canceled.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.17 <u>Saturdays, Sundays, Holidays,&nbsp;etc.</u> If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.18 <u>Construction</u>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule&nbsp;of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.19 <u>WAIVER OF JURY TRIAL</u>. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,&nbsp;IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">(Signature Pages&nbsp;Follow)</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">23<a name="23056-2-KS-05_PB_23_073404_3641"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=23,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=819821,FOLIO='23',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-05_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 08:07 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.58%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PROTAGONIST   THERAPEUTICS,&nbsp;INC.</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Address for Notice:</font></u></p>    </td>   </tr>
<tr>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.58%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="44%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Dinesh V. Patel,   Ph.D.</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name: Dinesh V. Patel,   Ph.D.</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">E-Mail:</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title: President and   Chief Executive Officer</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax:</font></p>    </td>   </tr>
<tr>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">With a copy to (which   shall not constitute notice):</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">24<a name="23056-2-KS-05_PB_24_073600_5250"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=24,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=459253,FOLIO='24',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-05_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 08:07 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name of Purchaser:</font></p>    </td>
<td width="63%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:63.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Signature   of Authorized Signatory of Purchaser</font></i>:</p>    </td>
<td width="63%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:63.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name of Authorized   Signatory:</font></p>    </td>
<td width="63%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:63.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title of Authorized   Signatory:</font></p>    </td>
<td width="63%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:63.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Email Address of   Authorized Signatory:</font></p>    </td>
<td width="63%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:63.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Facsimile Number of   Authorized Signatory:</font></p>    </td>
<td width="63%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:63.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="100%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Address for Notice to   Purchaser:</font></p>    </td>   </tr>
<tr>
<td width="100%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Address for Delivery of   Warrants to Purchaser (if not same as address for notice):</font></p>    </td>   </tr>
<tr>
<td width="100%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">DWAC for Shares:</font></p>    </td>   </tr>
<tr>
<td width="100%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subscription Amount: $</font></p>    </td>   </tr>
<tr>
<td width="100%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Shares:</font></p>    </td>   </tr>
<tr>
<td width="100%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Warrant Shares:</font></p>    </td>   </tr>
<tr>
<td width="100%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">EIN Number:</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font> Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i)&nbsp;the obligations of the above-signed to purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations of the Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii)&nbsp;the Closing shall occur on the third (3<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">rd</font>) Trading Day following the date of this Agreement and (iii)&nbsp;any condition to Closing contemplated by this Agreement (but prior to being disregarded by clause (i)&nbsp;above) that required delivery by the Company or the above-signed of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition and shall instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument, certificate or the like or purchase price (as applicable) to such other party on the Closing Date.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[SIGNATURE PAGES CONTINUE]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">25<a name="23056-2-KS-05_PB_25_073719_7672"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=25,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="3",CHK=704000,FOLIO='25',FILE="DISK106:[18ZCV2.18ZCV45602]23056-2-KS-05_ZCV45602.CHC",USER="CMATTI",CD='Sep  5 08:07 2018' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>a2236589zex-23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#18ZCV45601_4">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="kg45601_exhibit_23.1"> </A>
<A NAME="toc_kg45601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;23.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="kg45601_consent_of_independent__kg402318"> </A>
<A NAME="toc_kg45601_2"> </A></FONT> <FONT SIZE=2><B>  CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We hereby consent to the incorporation by reference in this Registration Statement on Form&nbsp;S-3 of Protagonist Therapeutics,&nbsp;Inc.
of our report dated March&nbsp;7, 2018 relating to the financial statements, which appears in Protagonist Therapeutics,&nbsp;Inc.'s Annual Report on Form&nbsp;10-K for the year ended
December&nbsp;31, 2017. We also consent to the reference to us under the heading "Experts" in such Registration Statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>/s/
PricewaterhouseCoopers LLP<BR>
San Jose, California<BR>
September&nbsp;6, 2018 </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="4",CHK=1007134,FOLIO='blank',FILE='DISK104:[18ZCV1.18ZCV45601]KG45601A.;4',USER='CHE108053',CD=';6-SEP-2018;15:38' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="18ZCV45601_4">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kg45601_1">Exhibit 23.1</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kg45601_2">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=CMATTI,SEQ=,EFW="2236589",CP="PROTAGONIST THERAPEUTICS, INC",DN="4" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g921274.jpg
<DESCRIPTION>G921274.JPG
<TEXT>
begin 644 g921274.jpg
M_]C_X  02D9)1@ ! 0$!+@$N  #__@!.35),3%]'4D%02$E#4SI;4%)/5$%'
M3TY)4U1?5$A%4D%0155424-37TE.0UU04D]404=/3DE35%]42$527T1,7U!-
M4U],3T=/+D504__; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_  !$( &X!M ,!(@ "$0$#$0'_Q  ?   !! (# 0$
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M SP<BQLT,-F/SW?ZBM(P'Y=%AH]2K>BD?) )?3[U#X3RY)!W0X^:_-@>1,"
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MA7=Y-KQVKSP 2JV<U5KQ/'-8G+>S#H=J>&=FT N_H-E1]-EOD ':YI'5DBC
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M-BP=5:ULF(618R<5R2+$N,<N"!?&/(O8,L(]M0,LXBO=%L:ELZ,XC%&1T>9
M^I KV._$QZB*SS:ORUW=%1%3MR-:K+![;QR"2&92T;?!T-;##[CN'V^H(!!'
M3L,ID[E9>QT.F7Z>=^1^G@_?^)V.J2?H8_WQ;'_Z+=V_]U2<O#<H\^AC_?%L
M?_HMW;_W=)R\-R1EO[4/^J3_ +VZ;I?U)_WV_P"Y>CAPX<K.I?1PX<X541.Z
MJB)^W_L3_&OZ$X='2=;>I+C)-6["H*!7I=7&'9#7UC!O>,AIDJMD##&8]G9S
M72E58S5[HGD9$<J-55Y7HC*.)/CK80RD#$G@^\*XC5$9XHDL?U]<1A$10G<,
M1X9!O1'"*KF/:BM5.3R[EZG^GGIZA-F[KW+KK6B%$IXL++,HK*VYGB;\N=64
M"F+?6:HBI^&OK)+E5S41%5R(L$'51ZIWIEY)-LI^)T>YM@YJ0CE7*=68?'PF
MKMCHCAM);2]F'HXMHBN:QRS68W(GE&YJ-F*G=$\F?M,_L\<F]8'P'(^&VJG[
M^XY6LTVQ.5+0T<G4EGCM1?A[9CDKU[D4RR*T=M%JW(I5$MFM^& F]%^@_K/@
M_349K"\EK6CB,Y-!8&1QP62Y0LQ1/7?WJ_?'+-5DB96#UW,]:2-C'!/[Y]NQ
M;A63XQE^,4V08?,AS,=GP8[ZU\)!C" +1,8V"^./M]%(@HB19$ C1FAD$X!!
M,5G;FTJJ)^:HG?X3NJ)W7]7SRFYH/U/),K,GT.LL/WY1WMC,1D.FU[6LV;-L
M1O(T48EWB>+A*4YU:K$*]:"<)BHC!2%;X\D_W1D_7ALK7<"1(SCJ#T71V5:K
MC6N%:[QO#LD5KB.5#9":;B%CEN,S6I_%**-.Q4J@1CT:A'..[9:WKCG>*4:T
M/JYZ2\]X9;KQ)'D,SA<1'RKARM&@62S%D\):M25H'(,BUFALF!&]O\3.4,C4
M4_I-B<_;F?TZ]1>'\FK3.STL;E<D_'>2LLC;C@DQ^4KP1SS*&[&F2:(3,/<]
MB$.$"5?:&]LZ;72NLM+2)51;;R+LFKSREKXWTLB[PS"8--=5V0VUL1GG+IX&
M6/G5M/70)'T_[H"Q#3PL.''WD'$CZ(VO\[R[U ]8Y-BD6R90:SH\ZR;8=U%C
MO?7UN.7&&7V+5M59R%;[ RY1?VU?%K8KWI(E) G38HWLJI)0*G@GIVZ@N-@6
M64=1&Y=XY[5V5@MA:OQ&)B\;-+V<5WG++D^89A:Y#..<KD5I)$.(ED\?X628
MSVL5ED+I2RWH6T-A$76VC:VFTY4%D"DSX=_66-;<9!:J)H'7.59C9OLGY)</
M&GM?>-QD$D@0(V+$^FAB& ?0N/?M&^B/(:J4L)ZB8&2U9#*L&8DGX[,9)?RF
M..#/P8V260;TB0B4,VR&/P=0S7HIZJ8.5[.4X5F%@@(9IL;%'FH0B:8.\V'D
MNQQI_M/*8^T>"!K?4B2=T1$5>ZHB=U_6OZ^<\\%;:UES##85%C!M($AJ.!-K
MI<>=#,U>W9PI,4A0$1>Z?+"._-.>_G28Y(YHTEAD26*15>.2-U>-T8!E='4E
M65@05920000='K0G1XW:.1&1T8JZ.I5T93IE96 *L#X((!!\$='*W/VCM%74
M/3#V15[;?S'OV3O_ (.Y/+(W$?V]T_Z2W]7TM5NO5>"[2K<=L)%K10<YQROR
M*+4V4N(L"3.KPV BLC2CPG.BE,)$>\"J-5\5[<E5I1!/'*P+!"20-;.U(\;\
M?7IF5#)&R @%@!L_ \@_^'3%?1=14]-OIU145%\-H?"IV_PP9YR4KFDZZUO@
M6H\/J-?ZQQ#'L#PF@2:E+BN*U<:FHJM+&PE6L](-=#8./'^KLILN=(]MJ>[*
MDF,[N\CE7=N(F<22RR $"21W /R S%@#^HWTI%[412=]JJN_OH ;Z.'#AQOI
M75;G[1VBKJ'IA[(J]MOYCW[)W_P=R>/\]%U%3TV^G5%147PVA\*G;_#!GG'U
M;>Z?]);^KZ6JW7JO!=I5N.V$BUHH.<XY7Y%%J;*7$6!)G5X; 161I1X3G12F
M$B/>!5&J^*]N;5KK6^!:CP^HU_K'$,>P/":!)J4N*XK5QJ:BJTL;"5:ST@UT
M-@X\?ZNRFRYTCVVI[LJ28SN[R.59;6%:G'6[3W)*9"WCM((D\ ?._P X_P #
MTR(B)WEV-,G:!]?[OG_L];MRN[ZRGI;9+OZ87JDZ=<?6]VI I(]9M;6\)HDL
M-E4%)$<"KR;%Q$4;)V=458S[IG49"*;+\>C5L2J_MY31(%W8BX*B+\*G=/U+
MQJ"=Z\BRQGR/!!^&4_*L/J#_ (@@$:(!Z7)&LJ%&^#]1\@CX(ZIV=%WKB[3Z
M;J"OT?U/:\R/:M!@JBQJ%DD28E#NC#:^L4<)N.Y=1Y4R'$RHE& /T<1]O,QC
M*(X1LB6DJW*)AFOWSW[13TX5^/23ZTTENW+,H4+_ *.OR\>%X-CXC.&]&.LK
MJ%DN76#0B+XJ9*^CED(SN@GM7N]LOF[NBSI4ZCI"3MUZ&UQGUQY 5<CLZ 4+
M+59%;X  [+Z0E5D[XHV?@^D);/C.'_%O$K/P\0ZA])ST[<<MX%Y6]*>MBSJT
M[9$9ET[)\EK%*W^2LJDR/(K6EGM:J^31SZ^2)KT:]&>36JDQI\?(WN/5E5SY
M98W'ML?K_>4@$_[*K]_)\]1Q'94=JRH5'@%E_,!_@=D?J3\#Z?%7G$]?=:7K
M8=2 LZR1'4>O:LXZ:TSF-76$?4&E\.8<,FPQK A6!3IE.9S^WU:U09D^YO+I
MT:QS"?2X_$B_071M*:>P;0&J<$TUK6L6HPG7F/0\=HHA'H:4449'%EV=E(1@
MTF7-U8FF7%U/4;'SK6=,EO:CBJB;OCV-X_B5-7X[BU'3XWC]1';$J:*@K(5/
M3U<1BJK(M=5UP(T&%':JJJ!C $-%55\>Z\S7&+-HS]B*@BAC&HXE\@?])CH;
M8_PT//U+$NQ0B/N8L7D;^DY^OZ ?0?\ KZ "M3]H>Z=<LRC#],=2>,U$NVHM
M7MRG!-EDB,+(=04&83:2UQC))@!-?[-''O:VPIK>Q?X"@'NJ@DIR17D/&;[T
M0>NOC^A] X+I3>.H<YS"7K"@KL1Q'-M=V6-'==XE4L6+11,BILGL:+Z"UHZM
MD6J985EC91;J-%#*+&K97NL-;/FPH=C$E0+"+'G09L<\29#E@%)BRXDD3P28
MLJ,9CPR(T@+WA. S'B,)[QD8YCG-5@F0^E9Z>N47\G)K;I2U8EI+DK+D-J85
MSCM2:0XBE>]^.X[=56/*TCU7W1)5M"5G\60;AHC>/16H#76O:B=UC8M&T9 8
M;).CLK]R/D@@@:&@>FWAD$IEB=5+ !@PV#K7Z'[#Z [^OD](_P!,/5EAWJTZ
M.ZKL%=KRVUG@;@S=,M?<7L"_RB= SS I,DN13ZZH%&K::96DG!+!JH]M:M,L
M5I#6">XHVUI]%;:ZBO1FZNLHHMC8"2XBVD!F+9QBY9#ZNHVIA$.Q=/Q_/-:Y
M,>*>":3%*0UE4F]N0*(ZQML4RF/6S5,2!=PU5IG4^C<8%ANGM=8;K7%QO:9U
M+A>/5M!"D2FC:)9LY($<1;&>\;6L+/L"RII6M1"2'(G/C:NE=2;QQQ^);AUO
MA6R\<>I'LJ,UQRLR&)&,5K6OE0/O".8U;,[-;VF5Q8DM/%%0R*B=L16XHGF0
M0EJDW:#$S?F':!I@V_))&R-_.M,"NSEX7=4;O F3>G \'9WK7V^GP?&]@[\1
M)UOK]]"4NG!83@[QJ+-\53'QV1JH\VP#)8SNL)+"JO9N/G(1Z*P,@=LD145K
MS%CM\D:P3>WJ ]1OJN/R3I:Z,-5WNOM,SH,HNZ-HYB8;[0>%PQ2;*1!RVPQY
MUE1X!CEN""X!<:@6609KG16,HXCX%.:Y">9B/Z1GIR1I3)@^E37SRL(\J#E3
MLTFPE<_R\FOK9F5'KR"3S7VP$C.")48HQM4;/%\&%:LUMK?%!X+K_ \0PG#1
M1WQ68OBF.U./T2!+&2(9'5M5%BQBO/'3VI!S,)(.Q7>\4BN<J@GI0GO@@E:4
M':&=E*(1K3!5WW$'9 ;P#H^=='MSO^621 AUW",$,PUY!)^-GY(UX\?IU4)^
MSQ.5_6;L<OBY&DZ:<G>GDWLJ(_8NLGHCD^41W9?E$541>_953YY;AW5I?7/4
M)K'+=0[7QV/E&"YI7+77-6=Y(YF*PC),*RK9T=S)=7<U,X,>RI[6$0<NNL(P
M)(7]V*UVEZEZ2NF;0^0R\KTSHG5FL,EGTQL=F7F$8;48]:2J(\J%.-4GF0 "
M,2O+,K8$DD9SE&X\2.14\A-5&J>I]U]S>@C4V$93C6&P\VSK8.<Q,?Q^KOF7
M,7$@TM1]/:9C*NKVI:B5MB>J*&IQ>*\KI4RYLV3Q5UG7TMK&5,\K7;:O K*[
M=BH"0"&0?TNX'0UK>_IKK,:""$B0@J-ECHD:/TU]=_&NH)=[^AYU@]/>>,V'
MT9YU.V165<V7.Q>939@#5&],1$_Y;%=8?>-%C^0O:!S8YK2AOJ,UH@U^IQ8"
M.1CL;58_]H3RP#->,F]2]5%<]X'W-WD.H\343!D4+R&V.Z5&O% GDKFGBW)Y
M1Q(AXZF\6O6:+IS];'HEW?5U\?-LT=T]YR9(H)^*;;_M?2I.-Y-,VDV'$$7$
M;:O81J(*19R<=LG#>-\JGB/<YC'UR>L'I*A5);X_4QT_"J0Q5FDL4W!KQT=(
MO;NAFN'D#R/:[NB,1C'/>Y4:QKG*B<D-;N(0EBK'*ZZ"M- 6;[C1!"L#].T>
M=[V>FA# VVCF9%/DA)  /CZ'R#_'[C^'4,/1UZ/<70EE<]6G6[FE;MG:&(UU
MIL2!B[[>RR+$<9NJ.KF7;\MSG,<I8ZPV#DU.\"RJY\F)&QJ@FQ_O-C;V6"#,
M@QR?9^*^9=]<>6WL=G]BUO3WGUE/5_NO<Q,@S7788C/<:)S%,XQ'^2G>+W6C
M(\?F]KF([?U5?6,U?GNJLLZ;.E&_-EX\\@2*'9NXX@K"IQBMP\SD9=8O@\J:
MR!,O[#(P-?67&3,C,QJ!CTB<"KEVMA/0]4Y_T(.C+)]&Z@S#J$V523<>S+?8
MJ&/B%!:17PK.GU10+)GTUE/A&8*57R\VM[*3=#@21,,/'X&-R"C$:64(W6>9
M:=F6T2LECLBAC([=*I/PG]U=,Q^ 3K9\D$I"QM/$D.BL7<[L"2"3V_WMG9V!
M\>/.OH1U*3UG]*.%=9N@,OTAF9RU1+3Z:[P[*HPFR)N%YW2H8N.9-&CO5&2P
MQRF/7W-<YP_O;'[&VK&GC$ECDAI\:TVKUL>B[ON\QG*<18F.9)- S),/O%L"
M:DW-75XWBK<IU_FH(JI%OHD$[OH[6L:2ZJ6O^XLWQF4.(VO!>RYI6>ZWU]M/
M'Y&*;*PC$L_QF4[W)&/YGCM3DU,4R#()AW5MS$F16R!L*1HY+!LD#1[O;*WO
MR!6M^RKQ2()H)/+1DZT?]I3YT? V/N 001OJ1+#[A#HQ21?AA\$;WHCZ_P#H
M$$=06XW]HEZ5YE%&E9;IOJ QW)%'WFT=/68'E-:(_DY/"#D),SQ]TL"-1'H:
M735A5:O98R$16\BYZR_5AZA/4%473/TZZMR?#,(S@PZN?A6.N=F>W]K"<7NV
MGN'TD=L#'L2*YL<]I3U#BADM"Y,CRQU"Z77$L5R/2'].*2<\@G2M@C'R"D,1
MD:VSN'':\KE>YL>)$RX,6*%JN5!1XP0@ Q&C"-@VM:CK]+=,W3_TZUA*K2&H
M, UE&D 9&G2,4QR!7VUJ$3FN&VZOU&6^NE:YJ.\K:SF.5_<BJKU5ROBQ0B/N
M0UI&D!VGNN.Q#XT0 S$E3Y&]G[$'1"#%8<=KRJ%/@]B_F(^WP-;_ $/\C\=1
MT^DGZ;DCHHP2\V%M-*Z;U#[2KX<+(AUDQMC5Z]PV.=EC!P*LGC&,%C:2+!!6
MN:V\;W8$RVBU]95&DU=''GSVW?:+T5>FC0W9%7MU!IW[)W_P89URPUQ)MN:)
MTWONFJ\>W1K+"=H4=+:_?E34YQC\#(H%=<?12:W[SAQK 11@F_039<3ZAC4)
M]/(,/OXO<BQDM-^*6S+MR'[B!X\:("KOX &@!]A\[\].-"#"84_*-  GS]0=
MG[D_7IAWHNHJ>FWTZHJ*B^&T/A4[?X8,\Y*5S2==:WP+4>'U&O\ 6.(8]@>$
MT"34I<5Q6KC4U%5I8V$JUGI!KH;!QX_U=E-ESI'MM3W94DQG=WD<J[MQF9Q)
M++( 0))'< _(#,6 /ZC?3B+VHBD[[55=_?0 WU$/ZY**OIT[71$55_=CIOX1
M.Z_SI8U^KB%_9X45.C/97=%3OU)YAV[IV[_^CW6/)KMEZLUSN3$9V!;5PG&M
M@X79R*Z788OEU3%NZ.9)J9H;*L/(KIK"1RE@SXX)D5[FJX,@(RL5'-14QFIM
M)ZCT1CLS$M-:XP[6.,V%Q(R"=0X30P<>JI5W+B0H,FU/"@#$$D\\.N@Q2R7-
M4CP1(XU7Q$U$>$ZBH];M/<TWNAO&M=JKK[[_ "]-F(^^)=C03MU]=[/\M>>J
M=7V@-KEZZ@*B*J?P=-=?/9>W_O[9?Z>6KM\2>H*+TA9([I<IZ.ZWH;65-#P2
M+?6X*<$:=-J:V+-M:XTX!*N5D516%F6&-5EU)KJ6QO@5\:VL8L%QE?M.U>D#
MI=WCDR9GN#06J-E96VHB4+<AS3"Z>_N$I8!9AH56DZ?'*=(,4MA.("/Y>V-\
ML[FHBD<JN(BQ8\*-'AQ BCQ8H QH\<+$&$$< VA"$0T_"P8A,8-C$^&L:C4^
M$XJ6TKQ5(PGFOON[]%'\J0"!HE3VD,"1L'76$B*R3.6\2:UKY7P?.SXWY\?/
M5/#I]]:/JZZ0K--)]86M,GVFF,D)!*F?NFX#U 4H6)X#%-M+RO=5Y]$$_P#'
M&L+J$"?+$]53+[ "QW#DJ-]H9Z.6T#YP-<=1)L@]E_MXV_#\, BRD YPQOOE
MSTE2.,^2C0.D-]T[!N^H^C<C5%R9C:6C=-[NJ?N+;^KL!V75-"<$>)F^*4N2
M-A,DHB&=7&LX<B56%=V:J&KI$4S7-:]A&O:UR,V3TCO3E2:E@G2GKWWT.DE!
M+-S):[W$7R1GW2N4K5K&[_"PUA_2*W\"A5OQQTST)3W2UI(W^6$##L8_7PQ4
M*#]E&_/DD^>D".P@[4E5E^GN*=@?;8WOQ]_\OI6#F&WMZV77577,3#5Q;"*X
M>.8[>N@$DW..Z:TK26\RQF#O\B..'%MLUR%UE<+$B!!6GR"_L@#@5,:AJ)4V
M->-C0HT.#'KXH!!AQ8X8@(S6(HAQ #8 <=&+Y(K&1V-$C?E.R=ORYJ&N]8:Y
MU'C43#=7X-B>O<5@_,7'L-H*S'*@1%8P;C_0U4:,$LHK6-0TLS2RC*G<QGK\
M\WOC%JR+!C5$$<4*]L:;V0#K9)^I.A_AY)))+D,7MABS=[N=LVM;^P ^PV?\
M?@?'5! ]CM[TH/4,M+M<429/UWF&9FHZ:X]ZII=IZ6S25:1(DFFM1Q9+0P+C
M'I,9D>X@PY[<;RNH=$F0"2*R37DFHR7[1WIN%B<J=C?3;MB=EPH#2LK,ERC!
M:'%13?IW/.V5DM;,O[5T*,=/$9P8NV1,$B/6/!>_P'.]NGIST7U%48,<WAJG
M!MGU4-Q25PLNH(=G)J2G;X&/2V;F#M:605O9"'J9T(K^S5>]RM:J-XP+TQ.@
M76EY#R3$NEG50+JO-]1!G7E5/S)T.0@_:8>*#,[/((@"B3^,$]D='".B21JR
M0U"\E-<J3A&LUY'F10I*-VJX'W(8$;))\ D;\$CIE8)HRPBD58V)(#+LKO7P
M-$'Q^H!U\#I[&/6CKNAI;AXF@?:U-;9. QZE8%T^#'EN$PCFM4C1J96->K6J
M]&HY6HJ]D.99K6L:UC&HUK41K6M1&M:UJ(B(B(B(B(B(B(B(B(B(B=N'*OJ9
MUKN8Y?C.O\4R/.,SNH&.8EB-)9Y'DE]:&]BOIZ6GB%G65A,*C7N:"+% 0KT8
MPA7^*#",A7L&ZG/UR^N%O'==W>83TOVMOI#38WG@1\KA@'"V_G,1S48^SE6Q
MDD$UU6R51SZ^HQSV<H%'5IK7(X\@QJ>%+!]H(VE<X9T<XI@%/*-$#N#<%!CV
M1J$I1_68QBE+=9Q(K"HQJ,)'G7M-CWU(BD1A0 >)PBL>3PIB)W<O;\U5?T_K
M5?T\O,93B>/\1*H<EBJ*PVH"ZVQ!&B2=@;V!K?R?%?;G=6]M#VC0+$>"=_3?
MT&O/C1._L/*M:NU1N'J7VE7X-K3&\GVGM++CE/X)*-9VYPL>SZ^]R7)KJ4YM
M925ZG&2UR'(;0%="0HVFDK(/' :T+TE?9^]78G&J\KZN<LD[5R961Y1=985.
ML\:UM5F7L0D&YR".Z%F&;N8OB,KXQL1IRJTC'5TX3F&<XKT*NG;#M9]&6-[G
M!709&PNH"?>Y+?Y"HD)8@Q:AR.WQK$<4#(>-KX]9 CU$B[DP@N<$]Y<39A7E
M>V/[$UW&KN1E,CPPDQHC%"R^'8J='1^4 ((';HD#9.CH+@K)VJ\@[V8!M'^B
M ?(\?4Z^=^/IKZE,-7:5U)I+'P8MJ+6^%:VQ\ @B^[,+QNKQX!_8:C&%G/KH
MP9-E)5$[DEV)Y<HSN[S&>]RN53NR)^2=O\7Q_FYSPY4DDDDDDGY).R?XD]31
MX&AX'V'@=(IL/IYU'LYAR9-B%>VU,QS4R&F8E)?C<Y55"+8U[1.E.:JJJ,L1
M30+_ +\+D1.1M;LZ+LQUW&FY)@TJ3G.*16%D3(B1FCRNFB,7R<0\**WV+R(
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M^)\?SG#Z/(>19#,9OE5*6I6H^^(<9@WQBTKCUJD,LE22=;Y%DS6YH!+[<43
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M:GA9+E<9TRG!]W32PGQF$FC>:79C$L&",:U\IQ'RS":,8_<>J,<U51FXZVM
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M(JN-F#J:9((@HZY-6RZ.&4CNWB/[SDM?6 >]5[#;*F1_-R*UG=RM1SF4]1N
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MW26;+Q0(N@3MI - G?CJXHU+64L1U,;6L9"U*0L56E#+:LRL3H+'! KRNQ)
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M5K3%]98U7.Q#'+>9:X_63L@M+>EKK.9<6%E CS)CI!YL4I/HVF+X1(3/"/&
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MG_6]25[%I::XTOD"V]366JUVN[FPKUL8$6<L&>'$)?M38:R1%6-+$BJ@Y(/
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:;Q!V$;D$$%D![6(*C1(.M#HX<.''^FNO_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g230562kii001.jpg
<DESCRIPTION>G230562KII001.JPG
<TEXT>
begin 644 g230562kii001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !# *T# 2(  A$! Q$!_\0
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MA1113(*LNF6,S;I;.W=CW:)2?Y5-%!% FV&-(U]$4 5)118ISDU9L*0@,"&
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L0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
